WO1999002956A2 - Method and devices for laser induced fluorescence attenuation spectroscopy (lifas) - Google Patents

Method and devices for laser induced fluorescence attenuation spectroscopy (lifas) Download PDF

Info

Publication number
WO1999002956A2
WO1999002956A2 PCT/US1998/011937 US9811937W WO9902956A2 WO 1999002956 A2 WO1999002956 A2 WO 1999002956A2 US 9811937 W US9811937 W US 9811937W WO 9902956 A2 WO9902956 A2 WO 9902956A2
Authority
WO
WIPO (PCT)
Prior art keywords
sample
radiation
return
modulated
sensor
Prior art date
Application number
PCT/US1998/011937
Other languages
French (fr)
Other versions
WO1999002956A3 (en
Inventor
Ramez E. Shehada
Vasilis Z. Marmarelis
Warren S. Grundfest
Original Assignee
Cedars-Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedars-Sinai Medical Center filed Critical Cedars-Sinai Medical Center
Priority to EP98926475A priority Critical patent/EP0995095B1/en
Priority to AU78306/98A priority patent/AU752061B2/en
Priority to JP2000502389A priority patent/JP2001509589A/en
Priority to DE69829664T priority patent/DE69829664D1/en
Publication of WO1999002956A2 publication Critical patent/WO1999002956A2/en
Publication of WO1999002956A3 publication Critical patent/WO1999002956A3/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64Fluorescence; Phosphorescence
    • G01N21/6486Measuring fluorescence of biological material, e.g. DNA, RNA, cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/0059Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
    • A61B5/0075Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence by spectroscopy, i.e. measuring spectra, e.g. Raman spectroscopy, infrared absorption spectroscopy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/0059Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
    • A61B5/0082Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence adapted for particular medical purposes
    • A61B5/0084Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence adapted for particular medical purposes for introduction into the body, e.g. by catheters
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/47Scattering, i.e. diffuse reflection
    • G01N21/49Scattering, i.e. diffuse reflection within a body or fluid
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64Fluorescence; Phosphorescence
    • G01N21/6402Atomic fluorescence; Laser induced fluorescence
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64Fluorescence; Phosphorescence
    • G01N21/6428Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/0059Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
    • A61B5/0071Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence by measuring fluorescence emission
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/0059Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
    • A61B5/0082Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence adapted for particular medical purposes
    • A61B5/0084Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence adapted for particular medical purposes for introduction into the body, e.g. by catheters
    • A61B5/0086Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence adapted for particular medical purposes for introduction into the body, e.g. by catheters using infrared radiation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/1455Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/72Signal processing specially adapted for physiological signals or for diagnostic purposes
    • A61B5/7235Details of waveform analysis
    • A61B5/7264Classification of physiological signals or data, e.g. using neural networks, statistical classifiers, expert systems or fuzzy systems
    • A61B5/7267Classification of physiological signals or data, e.g. using neural networks, statistical classifiers, expert systems or fuzzy systems involving training the classification device
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64Fluorescence; Phosphorescence
    • G01N21/645Specially adapted constructive features of fluorimeters
    • G01N2021/6484Optical fibres
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2201/00Features of devices classified in G01N21/00
    • G01N2201/06Illumination; Optics
    • G01N2201/061Sources
    • G01N2201/06193Secundary in-situ sources, e.g. fluorescent particles

Definitions

  • the present invention is directed to methods and devices for determining a spectroscopic characteristic of a sample utilizing laser induced fluorescence attenuation spectroscopy ("LIFAS"). More particularly, the invention is directed to methods and devices for measurement of the wavelength-dependent attenuation of the sample and subsequent restoration of the intrinsic laser induced fluorescence (“LIF”) for phsyioloical monitoring, biological tissue characterization and biochemical analysis.
  • LIFAS laser induced fluorescence attenuation spectroscopy
  • samples have been characterized by determining the attenuation and laser induced fluorescence ("LIF") .
  • LIF laser induced fluorescence
  • these spectroscopic properties can be utilized to determine a physical or physiological property of the sample .
  • the attenuation of a sample can be used to determine the concentration of a mixture components or turbidity of a fluid.
  • the LIF of a sample has been used in fields such as analytical chemistry, environmental monitoring, industrial inspection and medical diagnosis. In the medical field, for example, LIF spectroscopic techniques have been used for tissue characterization, malignant tumor identification, atherosclerotic plaque diagnosis, metabolism evaluation, and the like.
  • the attenuation or the absorption of a sample is determined by placing the sample between a light source and a detector and measuring any reduction in the intensity of the light as it passes through the sample .
  • the thickness of the sample and the wavelength of the incident light are important factors affecting the reliability of the resulting measurement.
  • it is necessary to place the sample between the light source and the detector it is difficult to perform attenuation measurements on certain types of samples, such as living tissue.
  • fiber optic techniques have been developed for the measurement of attenuation in which an optical fiber is used to guide the incident light to illuminate a sample inside a small chamber at the tip of a probe.
  • a reflector is placed on the opposite side of the chamber to reflect the incident light into a second fiber which is associated with a detector.
  • these techniques find limited application with materials, such as fluids, that can readily pass into the chamber in the tip of the probe .
  • LIFS laser induced fluorescence
  • spectroscopic techniques utilize various optical configurations in which a laser is directed at a sample using an optical fiber and the LIF from the sample is collected using a second optical fiber.
  • the same fiber can be used for excitation of the sample and the collection of LIF.
  • the LIF collected by the fiber is modulated by the sample, e.g. by the wavelength-dependent absorption and scattering of constituents of the sample. Therefore, existing LIFS methods are limited by the fact that the "intrinsic" or "true” fluorescence of the sample's fluorophores cannot be determined.
  • Recent reports have suggested measuring the diffuse reflectance spectrum of the tissue as a means for correcting the intrinsic LIF using Monte-Carlo mathematical formulations.
  • the tissue is deprived of oxygen and anaerobic respiration takes place. Consequently, the weak fluorophore NAD will be converted into the strong fluorophore reduced nicotinamide adenine dinucleotide ("NADH") .
  • NADH nicotinamide adenine dinucleotide
  • the LIF collected from the sample will reflect an increased contribution from NADH. This change is typically observed as a rise in the intensity of the LIF spectrum in the region of peak NADH emission, from about 470 to 490 nm.
  • the metabolic state of the tissue can be determined by measuring the relative change in LIF intensity at the wavelength of peak NADH emission as compared to the relative change of the LIF intensity of fluorophores that are normally present in the tissue, such as elastin or collagen.
  • the LIF of biological tissue is heavily modulated in the 390-450 nm range by the peak absorption of the main tissue chromophore, hemoglobin.
  • the measured LIF spectra has a valley in the 400-450 nm region that is associated with the hemoglobin absorption.
  • the measured LIF spectrum tissue appears to have a double peak instead of the single peak spectrum associated with the pure fluorophores of the tissue.
  • the LIF spectrum of normal tissue begins to resemble the spectrum associated with tissue suffering hypoxia or ischemia, which makes it more difficult to identify tissue abnormalities .
  • Organs such as the brain, heart and kidney are the most sensitive to oxygen deficiency and can suffer permanent damage following an ischemic or hypoxic event .
  • ischemic or hypoxic event Organs such as the brain, heart and kidney are the most sensitive to oxygen deficiency and can suffer permanent damage following an ischemic or hypoxic event .
  • ischemia i.e., ischemia
  • continuous monitoring of the organ is typically required.
  • Ischemia and hypoxia are both conditions that deprive tissue of oxygen, leading to anaerobic metabolism and the accumulation of the metabolic coenzyme NADH.
  • the coenzyme NADH is a fluorescent molecule. Therefore, ischemia and hypoxia can be indirectly detected using LIF techniques by sensing increased concentrations of NADH and interpreting its elevation as a sign of oxygen deficiency.
  • a common indicator of oxygen deficiency is the ratio between the LIF intensity at wavelengths associated with the peak fluorescence emission of NADH, collagen and elastin.
  • such methods have not been practically applied for the detection of ischemia because of several complications. First, these methods cannot determine whether the elevated NADH concentration is caused by ischemia, hypoxia or hypermetabolism.
  • the indicator ratios are calculated by normalizing the intensity of NADH peak fluorescence by that of collagen or elastin. Although the fluorescence of the structural proteins elastin and collagen does not vary with tissue oxygenation, the fluorescence with the site of measurement.
  • the intrinsic LIF of biological tissue have a single peak spectral profile resembling that of the pure structural proteins which are primarily elastin and collagen.
  • this single peak profile is modulated by the attenuation of hemoglobin, especially about 410 nm, to yield a distorted, double-peak spectrum.
  • the second spurious peak at about 470 nm results from the spectral valley created by heavy hemoglobin absorption at about 410 nm.
  • this second peak overlaps and obscures the peak fluorescence emission of NADH at about 470- 490 nm, which may impede ischemia detection techniques that are based on NADH concentration.
  • the methods and devices of the present invention will enable measurement of several LIF parameters that directly relate to the state of tissue perfusion and/or hemoglobin oxygenation. This offer superior accuracy over the currently available LIF techniques which detect ischemia and hypoxia indirectly by sensing an upsurge in NADH fluorescence.
  • the methods and devices of the present invention can directly indicate the presence and the level of hypoxia or ischemia.
  • the methods of the present invention utilize novel criteria for discrimination between normal and ischemic or hypoxic tissue.
  • the present invention is embodied in a system and related method for laser induced fluorescence attenuation spectroscopy ("LIFAS") in which the attenuation and intrinsic LIF of a sample can be determined.
  • the LIFAS system employs a source, a first sensor, a second sensor and a processor.
  • the source preferably a laser, emits light to irradiate a sample volume in a sample so that the sample volume produces return light, which preferably includes laser induced fluorescence.
  • the first sensor monitors the return light at a first distance from the sample volume and generates a plurality of signals representing the intensity of the return light in predetermined wavelength bands .
  • the second sensor monitors the return light at a second distance from the sample volume and generates a plurality of signals representing the intensity of the return light, preferably over the same wavelength bands.
  • the processor can be used to determine the wavelength-dependent attenuation of the sample using the signals of both sensors.
  • the measured attenuation will typically reflect the effects of both absorption and scattering by the sample.
  • the first and second detectors monitor return light from the sample volume at a location in proximity to the sample volume .
  • the attenuation can be used to restore the intrinsic LIF of the fluorophores of the sample. Once the attenuation and intrinsic fluorescence have been determined, these factors can be used in a variety of applications, including medical diagnosis.
  • the attenuation and fluorescence are used for the detection of ischemia and hypoxia of biological tissue. Ischemia and hypoxia are detected by monitoring spectral changes in the intrinsic LIF to detect a rise in the concentration of NADH in the tissue. Since ischemia is caused by a decrease in the blood content of the tissue, ischemic tissue will have lower concentrations of hemoglobin.
  • MAM can be used as an attenuation or fluorescence spectral classifier.
  • FIG. 1 is a schematic diagram of a spectroscopic system in accordance with the invention
  • FIG. 2 is a schematic diagram of a Laser Induced Fluorescence Attenuation Spectroscopy system ("LIFAS") in accordance with the present invention having an excitation waveguide and a first and second collection waveguides;
  • FIG. 3 is a schematic diagram of a LIFAS system in accordance with the present invention having a first excitation-collection waveguide and a second collection only waveguide;
  • FIG. 4 is schematic diagram of a LIFAS system for biomedical applications in which excitation radiation is used to induce fluorescence of tissue;
  • LIFAS Laser Induced Fluorescence Attenuation Spectroscopy system
  • FIGS. 5(a) and (b) are end perspective views of a LIFAS probe having an optical fiber and an optical fiber bundle as the central waveguide ;
  • FIGS. 6(a) and (b) are partial perspective views of an electrical subsystem used to synchronize a LIFAS system with the electrical activity of tissue using electrodes integrated into the optical probe;
  • FIGS. 7(a) and (b) are schematic diagrams showing the relative positions of the action potential and electrodes integrated into the optical probe; and FIGS. 7(c) and (d) are the corresponding action potential timing diagrams;
  • FIG. 8 is a perspective view of a probe incorporating a visible light source for probe positioning and a circular LED array for indicating the direction of contraction propagation;
  • FIGS. 9 (a) -(c) are partial perspective views of three LIFAS probes having waveguides arranged in different geometrical configurations adapted for different applications;
  • FIG. 10 is a schematic diagram of a biomedical LIFAS system in accordance with the invention in which a single optical detector is used to measure the return light from two collection fibers;
  • FIG. 11 is a block diagram of the method for determining the attenuation and the intrinsic fluorescence of a sample;
  • FIG. 12 is a graph of the attenuation spectrum measured from normal and ischemic renal cortex of rabbit kidney using LIFAS devices and methods in accordance with the invention
  • FIG. 13 is a scatter plot of the fluorescence intensity at 480 nm acquired from hypoxic (+) , normal (o) and hyperoxic (x) tissue through excitation-collection and collection-only waveguides;
  • FIG. 14 is a graph of the intensity I co ( ⁇ ) c of the signal measured by a collection-only waveguide from normal, hyperoxic and hypoxic tissue;
  • FIG. 15(a) is a graph of the modulated LIF spectra of normal and ischemic kidney, and
  • FIG. 15(b) is a graph of the intrinsic LIF spectra of normal and ischemic kidney;
  • FIGS. 16(a) and (b) are graphs of typical modulated LIF spectra of normal and ischemic kidney, respectively, depicting the difference in the symmetry of the main lobe;
  • FIGS. 17 (a) -(b) are graphs of the mean LIF intensity of live kidney and heart tissue and FIGS. 17 (c) - (d) are the corresponding LIFAS-derived attenuation spectra.
  • the present invention is embodied in a spectroscopic system 110 and related method for measuring the attenuation and/or optical rotation caused by a sample 114.
  • the spectroscopic system 110 shown in FIG. 1 includes a source 111 that produces radiation 112, which is directed at a sample volume 113 within the sample 114.
  • the source 111 is preferably a laser and the radiation 112 is preferably monochromatic ultraviolet (UV) , visible or infrared (IR) radiation 112. Nevertheless, the source 111 can be selected to produce other types of radiation, such as broad-band or polarized radiation, useful for a particular application.
  • UV monochromatic ultraviolet
  • IR infrared
  • the spectroscopic system 110 further includes a first sensor 116 displaced by a distance Zl from the sample volume 113, and a second sensor 118 displaced by a distance Z2 from the sample volume 113, which are used to monitor return radiation 120 from the sample 114.
  • the return radiation 120 will include fluorescence of the flurophores of the sample 114.
  • the sensors 116 and 118 each include an aperature 116a and 118a, respectively, through which the return radiation 120 is observed and collected.
  • the sensors 116 and 118 typically can only observe the events occurring within the volume defined by a solid angle emerging from the aperture of the sensor. This volume is known as the numerical aperture or the field of view of the sensor.
  • first and second sensors 116 and 118 include numerical apertures 117 and 119, respectively, that are adapted to receive a portion of the return radiation 120 from the sample 114.
  • the sensors 116 and 118 can be tilted at different angles ⁇ x and ⁇ 2 and selected to have different numerical apertures 117 and 119 so that the sensors 116 and 118 can selectively monitor return radiation 120 from all or part of the sample volume 113.
  • the sensors 116 and 118 each generate a signal 124a and 125a, respectively, representing the intensity I cl ( ⁇ ) and I c2 ( ⁇ ) and/or polarization of the return radiation 120.
  • the signals 124a and 125a are generated at a plurality of wavelengths within predetermined wavelength bands.
  • the signal 124a from the first sensor 116 and the signal 125a from the second sensor 118 are communicated by signal paths 124 and 125, respectively, to a processor 123.
  • the processor 123 processes the signals 124a and 125a to determine a spectral characteristic of interest, such as the attenuation and/or optical rotation of the return radiation 120 caused by the sample 114.
  • the sensors 116 and 118 are positioned at non-equivalent distances Zl and Z2 from the sample volume 113.
  • the first and second sensors 116 and 118 will be positioned so that one of the sensors will be in the immediate proximity of the sample volume 113 while the other sensor is positioned at a location adjacent to the first sensor, but displaced slightly further from the sample volume 113. It has been found that this arrangement advantageously improves the signal-to-noise ratio and, hence, measurement accuracy of the spectroscopic system 110.
  • the attenuation of the return radiation 120 is dependent on the distance traveled by the return radiation 120 through the sample 114.
  • the signal 124a measured by the first sensor 116 and the signal 125a measured by the second sensor 118 will suffer different attenuation where the distances Zl and Z2 from the sample volume 113 are not equivalent.
  • the processor 123 can be used to process the signals 124a and 125a to determine the wavelength-dependent attenuation of the sample 114.
  • the attenuation determined by the spectroscopic system 110 will reflect the effects of light absorption and scattering by the sample 114.
  • the attenuation of the sample 114 can be used to determine the intrinsic fluorescence 129 of the fluorophores in the sample volume 113. The methods by which the attenuation and intrinsic LIF are determined are discussed in detail below.
  • the source 111 can be any radiation source, such as a laser or a lamp emitting excitation radiation 112 at a wavelength capable of interacting with the sample 114.
  • the sensors 116 and 118 will preferably include a detector, which can be as simple as individual light-sensitive diodes with appropriate band pass filters, or more complicated sensors such as an optical spectrum analyzer.
  • the sensor is a suitable spectrograph or spectrometer equipped with a suitable sensor.
  • the sensor can include a multispectral CCD camera.
  • the source 111 is an XeCl excimer laser emitting monochromatic ultraviolet radiation at 308 nm.
  • Each of the sensors 116 and 118 is a spectrograph (Model FF250, ARIES Inc., Concorde, MA) associated with a 1024 element intensified photo diode array (PDA) to image the resolved spectrum.
  • PDA 1024 element intensified photo diode array
  • Each PDA is connected to an optical multichannel analyzer (OMA III, EG&G Princeton Applied Research Corporation, Princeton, NJ) .
  • OMA optical multichannel analyzer
  • the OMA reads the light spectrum imaged by the PDA to produce the signals 124a and 125a.
  • a 335 nm longpass filter (Schott WG335) is placed in front of the aperture of each of the sensors 116 and 118 to remove any backscattered 308 nm excitation radiation.
  • the processor 123 is a personal computer that is networked to each of the sensors 116 and 118 via the signal paths 124 and 125 to receive the signals 124a and 125a, respectively.
  • optical rotation is observed in optically active materials.
  • An optically active material is characterized by a lack of symmetry in its molecular or crystalline structure which causes a rotation of the plane of polarization in incident-plane-polarized radiation.
  • the extent to which the plane of polarization is rotated will typically vary from one optically active material to another.
  • the extent of rotation may depend on the number of molecules in the path of the radiation, the wavelength of the radiation, and the temperature of the material.
  • Anisotrophy is caused by a selective response of the sample to radiation travelling in different directions.
  • anisotrophy can result from microscopic inhomogenetics in the tissue structure.
  • Use of equivalent distances Zl and Z2 will minimize the contribution of the path- length-dependent attenuation to the overall attenuation measured by the system 110. Therefore, the optical rotation or anisotropy of the sample can be determined more easily.
  • the LIFA system 110 shown in FIG. 1 can be adapted to measure optical rotation by utilizing first and second sensors 116 and 118 which are adapted to measure the polarization-dependent intensity of the return radiation.
  • the first sensor 116 can be adapted to measure a first optical angle ⁇ x yielding the maximum intensity of the first portion 128 of the return radiation 120.
  • the second sensor 118 can be adapted to measure a second optical angle ⁇ 2 yielding the maximum intensity of the second portion 130 of the return light.
  • the optical rotation of the return light 120 will be given by the difference between the angles ⁇ x and ⁇ 2 , provided that the system has been properly calibrated.
  • the same sensor is used for determination of the attenuation of the sample will find utility for monitoring the optical rotation.
  • These sensors can be adapted to such measurements by placing a rotatable polarizing filter at each of the apertures 116a and 118a of the first and second sensors 116 and 118, respectively.
  • FIG. 2(a) An alternative embodiment of the present invention is shown in FIG. 2(a) .
  • the spectroscopic system 110 of FIG. 1 has been adapted as a Laser Induced Fluorescence Attenuation Spectroscopy ("LIFAS") system 210.
  • LIFAS Laser Induced Fluorescence Attenuation Spectroscopy
  • a source 211 emits laser radiation 212 at an intensity and a wavelength capable of inducing fluorescence of the sample 214.
  • the laser radiation 212 is transmitted through an excitation waveguide 215 to a sample volume 213 within the sample 214 where the laser radiation 212 excites local fluorophores in the sample volume 213 to emit intrinsic fluorescence 229.
  • the intrinsic fluorescence 229 of the fluorophores in the sample volume 213 is modulated, for example, by the absorption and scattering of the local chromophores (not shown) and scatterers (not shown) present in the sample 214, respectively.
  • Two collection waveguides 221 and 222 having apertures 221a and 222a and numerical aperatures 217 and 219 are disposed about the excitation waveguide 215.
  • the collection waveguides 221 and 222 may be positioned such that their apertures 221a and 222b are laterally displaced from the excitation waveguide 215 by the distances xl ' and x2 ' and/or axially displaced from the aperture 215a of the excitation waveguide 215 by the distances yl ' and y2 ' .
  • the lateral distances xl ' and x2 ' are small or zero.
  • the axial distances yl ' and y2 ' are preferably selected to be small and unequal, while one of the axial distances is preferably zero. Also, it is desirable to position the apertures 215a, 221a and 222a of the waveguides 215, 221 and 222 in close proximity to or in contact with the sample 214 during use of the LIFAS system 210, as shown in FIG. 2(a) .
  • FIG. 2(c) An alternative configuration of the collection waveguides is shown in FIG. 2(c).
  • the axial distances yl ' and y2 ' are both zero.
  • the lateral distances xl ' and x2 ' are selected to be small and unequal.
  • the apertures 240a and 242a of the waveguides 240 and 242 are oblique such that the fields of view 244 and 246 are directed toward the sample volume 213 and to advantageously encompass the bulk of the sample volume 213. As shown in FIG.
  • the distances zl' and z2 ' are directed along the respective axes of the numerical aperatures 244 and 246 and extend from the surface of the apertures 240a and 242a to the point of intersection of the axes of the numerical aperatures 244 and 246, respectively.
  • the collection waveguide 221 collects a first portion 228 of the return light 220 and transmits the first portion 228 of the return light 220 to a first sensor 216.
  • the first sensor 216 generates a first signal 224a, representing the intensity I cl ( ⁇ ) of the first portion 228 of the return light 220 at a plurality of wavelengths within predetermined wavelength bands.
  • the collection waveguide 222 collects a second portion 230 of the return light 220 and transmits the second portion 230 of the return light 220 to the second sensor 218.
  • the second sensor 218 generates a second signal 225a representing the intensity I c2 ( ⁇ ) of the second portion 230 of the return light 220 at a plurality of wavelengths preferably within the same wavelengths bands monitored by the first sensor 216.
  • the processor 223 then processes the first and second signals 224a and 225a to determine the wavelength-dependent attenuation of the sample 214. As discussed in detail, below, once the attenuation is known, either of the signals 224a or 225a can be processed to minimize the effects of attenuation and determine the intrinsic LIF 229 of the fluorophores in the sample volume 213. Alternatively, if the sensors 216 and 218 are selected to monitor the polarization of the first portion 228 and the second portion 230 of the return light 220, the processor 223 can be used to determine the optical rotation of the return light 220 caused by the sample 214.
  • the intensity and wavelength of the laser radiation 212 should be sufficient to create a sample volume 213 that is large enough to have some overlap with the numerical apertures 217 and 219 of the collection waveguides 221 and 222, respectively.
  • the numerical apertures 217 and 219 can be selected to encompass all or parts of the sample volume 213.
  • longpass filters are placed before the inputs of the sensors 216 and 218 to selectively block backscattered excitation radiation.
  • the source 211 is an Xe-Cl excimer laser emitting 308 nm ultraviolet excitation radiation 212.
  • the waveguides 215, 221 and 222 are advantageously comprised of optical fibers or optical fiber bundles, which can be integrated into a probe for ease of use and durability.
  • the optical bundle and fibers are made of fused silica which is transparent to ultraviolet radiation.
  • a 1.4 mm diameter optical bundle is used as the excitation waveguide 215 while the collection waveguides 221 and 222 are 0.4 mm optical fibers disposed about the excitation bundle.
  • the lateral range xl ' and x2 ' are equal to zero while the axial distance yl ' is about 0.6 mm and the axial distance y2 ' is about zero.
  • the probe may be configured within, for example, the shaft of a hypodermic needle, so that the in-vivo physiological or pathological properties of biological tissue can be determined.
  • each of the sensors 216 and 218 is a spectrograph (Model FF250, ARIES Inc., Concorde, MA) associated with a 1024 element intensified photo diode array (PDA) .
  • PDA 1024 element intensified photo diode array
  • Each PDA is connected to an optical multichannel analyzer (OMA III, EG&G Princeton Applied Research Corporation, Princeton, NJ) which measures the intensity of the light spectrum imaged by the PDA and produces the signals 224a and 225a.
  • OMA III optical multichannel analyzer
  • the processor 223 is a personal computer that is networked to each of the sensors 216 and 218 via the signal paths 224 and 225 to receive the signals 224a and 225a, respectively.
  • FIG. 11 illustrates the main steps involved in determining the wavelength-dependent attenuation coefficient ⁇ ( ⁇ ) and the intrinsic fluorescence I ⁇ ( ⁇ ) of a sample in accordance with the current invention.
  • the first and second portions 228 and 230 of the return light 220 experience different attenuation effects due to the unequal path lengths traversed by the return light 220 from the sample volume 213 to the apertures 221a and 222a of the collection waveguides 221 and 222.
  • the first portion 228 of the return light 220 collected by the aperture 221a travels an additional path-length of ⁇ yl'-y2' ⁇ through the tissue as compared to the second portion 230 of the return light 220 which is collected by the aperture 222a.
  • the first portion 228 of the return light 220 suffers more path-length-dependent attenuation as compared to the second portion 230 of the return light 220.
  • the signals 224a and 225a representing the intensity I cl ( ⁇ ) and I c2 ( ⁇ ) at different wavelengths will exhibit differing levels of modulation caused by the attenuation of the sample 214.
  • the signals 224a and 225a will also exhibit wavelength-dependent modulations caused by the instrumental effects.
  • the wavelength-dependent modulations due to the instrumental effects can be determined and, in turn, compensated for by conducting a calibration of the LIFAS system 210. System calibration can be performed using light from a standard lamp (Quartz Halogen Lamp, Model No. 63358, Oriel Instruments,
  • the processor 223 can be adapted to correct the measured intensities I c ⁇ ( ⁇ ) and I c2 ( ⁇ ) for modulations caused by the wavelength-dependent instrumental effects.
  • the corrected intensities I cl ( ⁇ ) c and I c2 ( ⁇ ) c representing the intensity of the first and second portions 228 and 230 of the return light 220 at different wavelengths can then used to determine the attenuation coefficient ⁇ ( ⁇ ) of the sample 214 as described below.
  • the regions ® and ⁇ , of FIG. 2(a) may be at an effective range, symbolized as "R, " from which the collection waveguides 221 and 222 collect the majority of the first and second portions of return light 228 and 230, respectively.
  • the effective range "R” will vary with the attenuation of the sample.
  • the regions ® and (D, are geometrically symmetric with respect to the aperture 215a of the excitation waveguide 215 and, hence, have identical intensity of the intrinsic fluorescence 229 represented by I ⁇ ( ⁇ ) .
  • the wavelength-dependent intensities I cl ( ⁇ ) c and I c2 ( ⁇ ) c can be described by the following equations:
  • I cl ( ⁇ ) c I ⁇ ( ⁇ ) e - ⁇ ( ⁇ ) - (R+yl,) (1)
  • the attenuation coefficient ⁇ ( ⁇ ) can be calculated independent of the value of "R” from (1) and (2) as follows:
  • the attenuation coefficient can be calculated as follows :
  • ⁇ ( ⁇ ) ⁇ l/ ⁇ z2'-zl' ⁇ ln ⁇ I cl ( ⁇ ) c /I c2 ( ⁇ ) c ⁇ (4)
  • the intrinsic fluorescence, I ⁇ ( ⁇ ) can be restored from either of the signals I cl ( ⁇ ) c or I c2 ( ⁇ ) c (preferably I c2 ( ⁇ ) c where y2 ' « yl ' ) by assuming an average effective range "R" from which most of the intrinsic fluorescence is collected.
  • the constant "R” is approximately about 0.2 mm at 308 nm excitation radiation. Therefore, the intrinsic fluorescence I ⁇ ( ⁇ ) can be obtained by substituting the measured I c2 ( ⁇ ) c into equation (2) and solving for I ⁇ ( ⁇ ) using the constant R and the known value y2 ' :
  • I ⁇ ( ⁇ ) I c2 ( ⁇ ) c e ⁇ ( ⁇ ) - (R+y2,) (5)
  • the absorbance A( ⁇ ) and the percent transmittance %T ( ⁇ ) of the sample can be calculated as follows:
  • a ( ⁇ ) log ⁇ l c2 ( ⁇ ) c /I cl ( ⁇ ) c ⁇ ( 6 )
  • the source 311 emits laser radiation 312 at a wavelength and intensity capable of inducing fluorescence of the sample 314.
  • the laser radiation 312 is reflected by a dichroic mirror 326 into an excitation-collection waveguide 321, which transmits the laser radiation 312 to the sample volume 313 where the laser radiation 312 excites local fluorophores to emit intrinsic fluorescence 329.
  • the intensity of the laser 312 should be sufficient to create a sample volume 313 that overlaps with the numerical aperture 319 of the collection-only waveguide 322.
  • the dimensions of the sample volume 313 will also depend on the numerical aperture of the excitation-collection waveguide 321, on the wavelength and intensity of the excitation radiation 312 and on the optical properties of the sample 314.
  • the intrinsic fluorescence 329 is modulated, for example, by the absorption and scattering of the local chromophores (not shown) and scatterers (not shown) of the sample 314.
  • the excitation-collection waveguide 321 collects a first portion 328 of the return light 320 directly from the sample volume 313.
  • the first portion 328 of the return light 320 is transmitted through the dichroic mirror 326 to the first sensor 316.
  • the first sensor 316 generates a first signal 324a representing the intensity I xc ( ⁇ ) of the first portion 328 of the return light 320 at a plurality of wavelengths within a predetermined wavelength band.
  • the collection-only waveguide 322 may be positioned such that the aperture 322a is laterally displaced from the excitation-collection waveguide 321 by the distance x3 and axially displaced from the aperture 321a of the excitation- collection waveguide 321 by the range y3.
  • the lateral distance x3 is zero while the axial distance y3 is non-zero.
  • the apertures 321a and 322a of the waveguides 321 and 322 are preferably positioned in close proximity to or in contact with the sample 314 during use of the LIFAS system 310, as shown in FIG. 3(a).
  • the numerical aperture 319 of the collection-only waveguide 322 is selected to include at least a portion of the sample volume 313.
  • the collection-only waveguide 322 collects a second portion
  • the second sensor 318 generates a second signal 325a representing the intensity I co ( ⁇ ) of the second portion 330 of the return light 320 at a plurality of wavelengths preferably within the same wavelength bands as the signal 324a generated by the first sensor 316.
  • a longpass filter is placed in front of the aperture of each of the sensors 316 and 318 to selectively block backscattered excitation radiation. In the embodiment shown in FIG.
  • the first and second portions 328 and 330 of the return light 320 experience different attenuation effects due to the unequal path-lengths traversed by the return light 320 from the sample volume 313 to the apertures 321a and 322a of the waveguides 321 and 322, respectively.
  • the second portion 330 of the return light 220 collected by the aperture 322a travels an additional path-length through the tissue as compared to the first portion 328 of the return light 320 which is collected by the aperture 321a directly from the sample volume 313.
  • the first portion 328 of the return light 320 suffers less path-length-dependent attenuation as compared to the second portion 330 of the return light 320.
  • the signals 324a and 325a representing intensity I xc ( ⁇ ) and I co ( ⁇ ) at different wavelengths will exhibit different levels of modulation caused by the sample 314.
  • the signals 324a and 325a will also exhibit wavelength- dependent modulations caused by the instrumental effects.
  • the wavelength-dependent modulations due to instrumental effects can be determined and, in turn, compensated for by conducting a calibration of the LIFAS system 310. System calibration is performed using light from a standard lamp (Quartz Halogen Lamp, Model No. 63358, Oriel Instruments, Stratford, CT) having a predetermined continuous spectrum to measure the wavelength- dependent instrumental effects of the LIFAS system 310.
  • the processor 323 can be adapted to correct the measured intensities I xc ( ⁇ ) and I co ( ⁇ ) for modulations caused by the wavelength-dependent instrumental effects.
  • the corrected intensities I xc ( ⁇ ) c and I co ( ⁇ ) c representing the intensity of the first and second portions 328 and 330 of the return light 320 at different wavelengths can then be used by the processor 323 to determine the wavelength-dependent attenuation ⁇ ( ⁇ ) of the sample 314.
  • either of the signals 324a or 325a, preferably 324a can be corrected for the effects of attenuation to restore the intrinsic LIF 329 of the fluorophores in the sample volume 313.
  • the source 311 is an Xe-Cl excimer laser emitting ultraviolet excitation radiation at a wavelength of 308 nm.
  • the waveguides 321 and 322 are advantageously comprised of optical fibers or optical fiber bundles, which can be integrated into a probe for ease of use and durability.
  • a 1.4 mm diameter optical bundle and a 0. mm optical fiber are used as the excitation-collection and the collection- only waveguides, respectively.
  • the collection-only waveguide is a plurality of 0.4 mm optical fibers disposed about the periphery of the excitation-collection waveguide.
  • the optical bundle and fibers are made of fused silica which is transparent to the 308 nm ultraviolet radiation.
  • the probe may be configured within, for example, the shaft of a hypodermic needle, so that the in-vivo physiological or pathological properties of biological tissue can be determined.
  • Each of the sensors 316 and 318 is a spectrograph (Model FF250, ARIES Inc., Concorde, MA) associated with a 1024 element intensified photo diode array (PDA) to image the resolved spectrum.
  • PDA 1024 element intensified photo diode array
  • Each PDA is connected to an optical multichannel analyzer (OMA III, EG&G Princeton Applied Research Corporation, Princeton, NJ) which measures the intensity of the light spectrum imaged by the PDA and produce the signals 324a and 325a.
  • OMA III optical multichannel analyzer
  • the processor 323 is a personal computer that is networked to each of the sensors 316 and 318 via the signal paths 324 and 325 to receive the signals 324a and 325a, respectively.
  • the method of determining the attenuation coefficient ⁇ ( ⁇ ) and the intrinsic fluorescence I ⁇ ( ⁇ ) of a sample using the embodiment of FIG. 3(a) in accordance with the current invention is as follows.
  • "D" represents the effective range, from which the collection waveguide 321 collects a majority of the portion 328 of the return light 320.
  • the portion 328 of the return light 320 is collected directly from the sample volume 313 by the excitation-collection waveguide 321. Therefore, the wavelength-dependent intensity I xc ( ⁇ ) c of the portion 328 of the return light 320 collected by the excitation-collection waveguide 321 will be substantially similar to the wavelength-dependent intensity of the return light 320, represented as I 0 ( ⁇ ).
  • the return light 320 with the intensity I 0 ( ⁇ ) will suffer additional wavelength-dependent attenuation as it travels the extra path-length to reach the aperture 322a and is collected as the second portion 330 of the return light 320 with the intensity I co ( ⁇ ) c .
  • the wavelength-dependent intensity I co ( ⁇ ) c can be approximated by the following equations :
  • the attenuation coefficient can be approximated as follows:
  • the intrinsic fluorescence, I ⁇ ( ⁇ ) can be restored from either of the signals I xc ( ⁇ ) c or I co ( ⁇ ) c , preferably I xc ( ⁇ ) c , by assuming an average effective range "D" from which most of the intrinsic fluorescence is collected.
  • the constant "D” is approximately about 0.2 mm at 308 nm excitation radiation.
  • I ⁇ ( ⁇ ) I xc ( ⁇ ) c e ⁇ ( ⁇ ) - D (12)
  • the measured attenuation may account for absorption and/or scattering depending on the wavelength band of interest and the nature of the sample. Below about 600 nm, the optical attenuation of biological tissue is primarily due to absorption and, hence, the attenuation coefficient ⁇ ( ⁇ ) will represent absorptivity a ( ⁇ ) . Also, the absorbance A( ⁇ ) and the percent transmittance %T ( ⁇ ) of such samples can be calculated as follows:
  • a LIFAS system 410 in accordance with the present invention has been adapted for biomedical applications.
  • the LIFAS system 410 has been adapted to determine the optical attenuation of biological tissue.
  • the laser 411 emits radiation 412 at a wavelength capable of exciting the tissue 414 to emit fluorescence.
  • the radiation 412 is directed through an iris 440 at a dichroic mirror 442 which reflects the radiation 412 onto a lens 444 which focuses the radiation 412 onto the proximal tip 445 of an optical fiber 446.
  • the adjustable iris 440 is advantageously used to reduce the energy of the radiation 412.
  • the adjustable iris 440 can be replaced by any suitable attenuator.
  • the probe 448 includes a central optical fiber 446 that is used as the excitation-collection fiber and peripheral optical fibers 450a-h are used as the collection-only fibers.
  • the distal end of the optical fibers 446 and 450a-h are incorporated into the optical probe 448.
  • the aperture 448a the optical fiber probe 448 is placed in proximity to the tissue 414 so that the aperture 446a of the excitation-collection fiber 446 and apertures 451a-h of the collection-only fibers 450a-h are in contact with the tissue 414. As shown in a partial perspective view in FIG.
  • the optical fiber probe 448 includes a central optical fiber 446 and a plurality of optical fibers 450a-h disposed about the periphery of the central optical fiber 446.
  • the apertures 451a-h of the distal ends of the collection-only fibers 450a-h are axially displaced by a small distance y3 with respect to the aperture 446a of the excitation-collection fiber 446.
  • the return light 420 collected by apertures 451a-h of the collection-only fibers 450a-h pool into the aperture 418a of the sensor 418.
  • the optical fibers 446 and 450a-h can advantageously be replaced by optical fiber bundles in order to obtain greater flexibility and durability.
  • the central optical fiber 446 can be replaced with an optical fiber bundle 454.
  • the excitation radiation 412 is transmitted through the optical fiber 446 to the tissue 414 to induce intrinsic fluorescence of the fluorophores of the tissue 414.
  • the intrinsic fluorescence is modulated, for example, by the chromophores and/or scatterers of the tissue 414.
  • a first portion 428 of the return light 420 is collected by the optical fiber 446 from the tissue volume that is directly irradiated by the excitation radiation 412 and transmitted through the optical fiber 446 to a first lens 444 where the return light is directed through the dichroic mirror 442 and then focused by a second lens 445 onto the aperture 416a of a first sensor 416.
  • the collection-only optical fibers 450a-h collect a second portion 430 of the return light 420 and transmit the second portion 430 of the return light 420 to the second sensor 418.
  • longpass filters are placed in front of the apertures 416a and 418a of the sensors 416 and 418 to selectively block backscattered excitation radiation.
  • a first signal 424a and a second signal 425a representing the intensity of the first and second portions 428 and 430, respectively, of the return light 420 are generated by the first and second sensors 416 and 418 and transmitted via signal paths 424 and 425 to the processor 423.
  • the processor 423 uses the first and second signals 424a and 425a generated by the detectors 416 and 418 to determine the wavelength-dependent attenuation of the sample 414 using equations (8), (9) and (10) as described in the previous embodiment .
  • an illumination source 490 emitting visible light 492 is mounted on the probe 448 to act as a spotlight for the operator. Because room illumination can contaminate the spectral measurements of the system 410 by adding background light, use of the illumination source 490 will allow the operator to see and accurately position the probe 448 under low-light conditions.
  • the illumination source 490 is configured to illuminate the sample at all times, except when the LIFAS system is monitoring return light from the sample 414.
  • the biological electrical signal arising in nerves or contractile tissue, such as muscle, is known as the "action potential" and is caused by sudden changes in the ion conductivity of the cell membrane.
  • the occurrence of an action potential in contractile tissue initiates a contraction.
  • the action potential propagates and spreads in a wave-like manner to induce a local myocardial contraction wherever it travels.
  • An action potential propagating in the tissue local to the aperture 448a of the probe 448 can be detected by the electrode
  • the amplified action potential 468 is transmitted to the processor 423 to trigger the acquisition process of the LIFAS system 410 at a pre-selected phase of the tissue contraction or of the cardiac cycle, whichever is applicable .
  • a plurality of electrodes or fibers with a conductive coating can be distributed circumferentially about the tip of the optical fiber probe 448.
  • the probe 448 can be equipped with three electrodes 470, 472 and 474 arranged in a triangular configuration.
  • the action potentials measured by each of the electrodes 470, 472 and 474 are amplified through separate channels of the amplifier 460 and transmitted to the processor 423.
  • the processor 423 processes the received signals to determine the direction of propagation of the contraction vector 462.
  • the processor detects the phase lead/lag between the action potentials collected by the electrodes 470, 472 and 474 to determine the orientation of the contraction vector 462 with respect to the location of the electrodes 470, 472 and 474.
  • the contraction vector 462 shown in FIG. 7(a) is propagating from the tissue site 476a to the site 478a and, hence, as shown in FIG. 7(c), the action potential 474a arrives before the action potential 472a which in turn arrives before the action potential 470a.
  • the phase difference or time delay between a pair of action potentials indicates how the contraction vector 462 is centered between the location of the corresponding pair of electrodes.
  • the contraction vector 462 propagates from the tissue site 476b to the site 478b.
  • the corresponding time of arrival of action potentials 470b, 472b and 474b will vary.
  • the processor 423 processes the signals and indicates the direction of the propagation of the contraction to the system operator.
  • the direction of propagation can be indicated, for example, by a circular array 496 of light emitting diodes (LED) 498 mounted cirumferentially on the probe 448, as shown in FIG. 8.
  • the processor 423 transmits a signal to the LED array 496 so that, for example, only the LED element pointing in the direction of contraction propagation would glow.
  • the amplifier 460 can be replaced by any device that can measure the electrical activity of biological tissue such as a differential amplifier, an electrocardiogram (ECG) , an electromyogram (EMG) , an electroencephalogram (EEG) , depending on the LIFAS application.
  • ECG electrocardiogram
  • EMG electromyogram
  • EEG electroencephalogram
  • optical fibers with a metallic or electrically conductive coating can be used in place of one or all of the electrodes 464, 470, 472 or 474 to measure the action potential of the tissue.
  • conventional ECG is generally not suitable for triggering the acquisition of LIFS or LIFAS systems, since it does not accurately indicate the instantaneous state of myocardial contraction at the sample volume.
  • customary ECG using limb or chest leads can be used to trigger data acquisition of the LIFAS system 410 where the sample 414 is non-contractile tissue.
  • the light source 411 is preferably a lamp or a laser that emits ultraviolet, visible or infrared radiation.
  • the source 411 is an XeCl excimer laser emitting pulses of ultraviolet excitation radiation at 308 nm.
  • the optical components used in the acquisition system be made of synthetic quartz (fused silica) to ensures maximal ultraviolet transmission and minimal instrumental fluorescence.
  • a nitrogen laser, a helium-cadmium laser, a frequency-multiplied laser, a solid-state laser, an arc lamp or a light-emitting diode can be used as the light source 411.
  • the energy of the excitation light 412 is typically between 0.001-lOm Joules. However, it will be appreciated that the selected energy level should be low enough to avoid tissue ablation and/or photobleaching while still being adequate to produce detectable LIF.
  • the sensors 416 and 418 are each comprised of a spectrograph (Model FF250, ARIES Inc., Concorde, MA) associated with a 1024 element intensified photo diode array (PDA) detector.
  • An optional low fluorescence, long-pass filter (not shown) with a cutoff wavelength above 308 nm, preferably 335 nm (Schott WG335) , is placed before the entrance slit of each spectrograph to selectively block any backscattered excitation radiation from reaching the sensors 416 and 418.
  • the entrance slit of the spectrograph preferably has a width of 100 micrometers.
  • the spectrograph uses a 150 lines per millimeter diffraction grating to disperse the incoming return light 420 into its spectral components.
  • the spectrum formed by the spectrograph is imaged by a detector, preferably an intensified linear photodiode array (Model 1420, EG&G Princeton Applied Research Corporation, Princeton, NJ) facing the output port of the spectrograph.
  • the photodiode array generates a plurality of electrical signals representing the intensity of the return light 420 at wavelengths within predetermined wavelength bands.
  • the sensors can be constructed of any suitable materials, such as individual light- sensitive diodes with appropriate band-pass filters for the analysis of spectral bands of the return light or an optical spectrum analyzer ("OSA”) for analysis of a broader spectrum. Selection of the return light monitoring device will depend on a variety of factors, including cost, accuracy, resolution, and whether the user is interested in monitoring a single wavelength, a wavelength band or an entire spectrum.
  • the optical fiber probe includes a central excitation-collection optical fiber or optical fiber bundle with a plurality of collection-only optical fibers disposed around its periphery
  • the probe can take many forms.
  • the central optical fiber can be used as the collection-only waveguide while all or some of the peripheral fibers can be used for excitation-collection or collection-only. The latter arrangement is preferred when testing highly-attenuating samples to achieve a better signal-to-noise ratio.
  • FIG. 9 shows three alternative geometrical configurations of the collection-only optical fibers 950a-h about the excitation-collection waveguide 946.
  • the collection-only waveguides 950a-h are arranged about the excitation-collection waveguide 946 so that their apertures have a helical configuration.
  • each successive collection-only waveguide is shifted axially away from the aperture 947 of the excitation-collection waveguide 946, the return light collected by each of the collection-only waveguides 950a-h will be attenuated in varying degrees.
  • Use of a probe arrangement having a plurality of collection distances will be useful in measuring the polarization and/or the attenuation of especially, a sample having a higher sensitivity to attenuation due to absorption.
  • a probe incorporating a plurality of collection distances have application to a larger variety of samples. For example, where the sample is highly attenuating, the collection- only waveguides having apertures close to the excitation site can be used to collect the return light. Where the sample is lightly attenuating, the return light collected by the waveguides having apertures that are further from the excitation site will be useful in determining the attenuation.
  • the collection-only waveguides 950a-c are displaced laterally with respect to the excitation-collection waveguide 946.
  • Such a probe configuration will be useful in measuring the polarization and/or the attenuation of the sample where the sample has a higher sensitivity to attenuation due to scattering.
  • the return light collected by the waveguide 950c will be useful in measuring attenuation of a lightly attenuating sample.
  • the return light measured by the closest waveguide 950a will be useful in measuring the attenuation of a heavily-attenuating sample.
  • the collection-only waveguides 950a-c are both axially and laterally displaced with respect to the excitation-collection waveguide 946. This configuration combines the advantages of both of the aforementioned configurations shown in FIGS. 9(a) and 9(b).
  • a single sensor 1016 and an associated optical multiplexer 1080 are utilized.
  • the multiplexer 1080 is used to switch the input of the sensor 1016 between the excitation- collection optical path (1046, 1044, 1042, 1049, 1046') and the collection-only optical path (1050) such that the return light from each pathway is measured sequentially.
  • the processor 1023 sends trigger signals to the source 1011, the sensor 1016 and the optical multiplexer 1080 to synchronize their actions. If the source 1011 is a pulsed laser, two or more radiation pulses are typically required to acquire a single attenuation measurement using the multiplexed system 1010.
  • a single laser pulse can be used if the laser pulse lasts long enough to sustain the emission of return light 1020 during the minimum period of time required by the optical multiplexer 1080 and associated sensor 1016 to acquire the spectral measurements from both the excitation-collection and the collection only optical paths.
  • the preferred embodiment of the LIFAS system 1010 is similar to that of 410, except that the system 1010 utilizes an electromagnetic dual port shutter as the optical multiplexer 1080 associated with a single sensor 1016 in a configuration where the portion 1028 and the portion 1030 of the return light 1020 are measured sequentially.
  • the LIFAS methods and devices of the present invention can be used advantageously for the in-vivo diagnosis of hypoxia and ischemia of biological tissue.
  • Hypoxia is a deficiency in the amount of oxygen reaching the tissue, e.g., due to pneumonia
  • ischemia is a localized reduction in arterial blood perfusion, e . g. , due to a narrowing of arteries by spasm or disease.
  • Ischemia can also result from hemorrhage of an arterial wound or during surgical procedure that temporarily interrupts the blood flow to a body region.
  • the present invention describes new criteria and methods for the discrimination between normal, ischemic and hypoxic biological tissue, including, in particular renal and myocardial tissue, as follows.
  • LIFAS laser induced fluorescence attenuation
  • the LIFAS-derived LIFA spectra of normal and ischemic rabbit kidney are shown in FIG. 12.
  • the LIFA spectra shown in FIG. 12 are acquired using a LIFAS system employing 308 nm excitation radiation produced by an XeCl excimer laser.
  • This LIFAS system uses a 335 nm longpass filter (Schott WG335) to cutoff backscattered excitation radiation form the collected return light.
  • the LIFA values below 350 nm are not reliable.
  • the LIFA values in the wavelength band about 480 nm have the highest signal-to-noise ratio and hence measurement accuracy.
  • the LIFA of ischemic tissue is lower than the LIFA of normal tissue over the entire spectrum and is particularly low in the region from 350 to 450 nm.
  • the LIFA, absorbance or percent transmittance at a predetermined wavelength or wavelength bands can be used for the detection of ischemia or hypoxia.
  • predictive models, spectral recognition techniques and associated classifiers can be applied to identify whether a given LIFA, absorbance or percent transmittance spectrum has been acquired from normal, ischemic or hypoxic tissue.
  • the classifiers can be initially trained with LIFA, at a predetermined wavelength or wavelength bands acquired from tissue with a known state of perfusion or oxygenation.
  • the [I xc (480) c , I co (480) c ] from normal and oxygen deficient tissue tend to cluster in two linearly separable regions of the two dimensional I xc ( ⁇ ) c -I co ( ⁇ ) c space.
  • a simple linear or nonlinear classifier function can be trained on a set of [I xc ( ⁇ ) c, I co ( ⁇ ) c ] pairs measured using a LIFAS system from normal, ischemic and hypoxic tissue.
  • Other classifiers such as artificial neural networks (ANN) are also being used.
  • the trained classifier function can then be used to classify an unknown [I xc ( ⁇ ) c , I co ( ⁇ ) c ] pair as normal, ischemic or hypoxic.
  • a "nearest neighbor” (NN) classifier has been found to perform satisfactorily.
  • the NN classifier checks the proximity of an unknown [I xc (480) c , I co (480) c ] pair to clusters of predetermined [I xc (480) c , I co (480) c ] pairs measured from known normal, ischemic and hypoxic tissue.
  • Other classifiers such as artificial neural networks (ANN) can also be utilized.
  • ANN artificial neural networks
  • [I xc ( ⁇ ) c , I co ( ⁇ ) c ] at other single or multiple pre-selected wavelengths can also be used.
  • ⁇ max _ ⁇ An additional parameter for the classification of normal, ischemic and hypoxic tissue, is the wavelength of the peak transmittance of the tissue, symbolized hereafter as ⁇ max _ ⁇ , especially in the 450-500 nm band.
  • ⁇ max _ ⁇ is the wavelength of the peak I co ( ⁇ ) c in the 450-500 nm band, symbolized hereafter as ⁇ , instruct ax _ co .
  • Both ⁇ max _ ⁇ and meticulous ax _ co shift towards shorter wavelengths as the hemoglobin in the tissue becomes deoxygenated .
  • FIG. 14 shows I co ( ⁇ ) c spectra that are acquired using the LIFAS system shown in FIG.
  • ⁇ max _ co shifts to a shorter wavelength as the tissue becomes hypoxic; whereas the ⁇ ma ⁇ - co °f normal tissue shifts to a longer wavelength as the tissue becomes hyperoxic.
  • ⁇ max _ co varies between about 480 and 500 nm as blood or hemoglobin oxygenation varies between deoxygenated to oxygenated, respectively.
  • a separation border can be identified at about 489.5 nm to separate ⁇ max _ co of normal tissue (peaks above 489.5 nm) from hypoxic/ischemic tissue (peaks below 489.5 nm) .
  • a simple classifier can be trained to identify tissue as hypoxic if its ⁇ raax _ co is below 489.5, and vice versa.
  • the degree of hypoxia is determined from the magnitude of the shift in ⁇ max . c0 from the normal value, the smaller the shift the subtle the hypoxia.
  • the presence of renal or myocardial ischemia can be detected from the shape of the main lobe of the common LIF (e.g. I xc ( ⁇ ) c ) spectrum in the wavelength band 350-450 nm.
  • the common LIF can be acquired via an excitation-collection waveguide of a LIFAS or a conventional LIFS system.
  • FIGS. 16(a) and (b) show typical LIF spectra acquired from normal and ischemic rabbit kidneys at an excitation wavelength of 308 nm.
  • the shape of the main lobe of the LIF acquired from normal tissue is skewed to the right (a positive skewness value) .
  • Skewness can be measured by a single parameter which indicates the degree of asymmetry of a lobe or curve around its mean value. For a symmetrical lobe the skewness is zero, however for an asymmetrical lobe the skewness can be either positive or negative depending on the shape.
  • the skewness "S" is given by:
  • X is the mean intensity of the lobe
  • is the wavelength
  • is the number of wavelength measurements in the lobe.
  • tissue ischemia can be detected by monitoring the skewness of the main lobe of a common (i.e. modulated) LIF acquired using an excitation-collection fiber from the tissue.
  • a zero or negative skewness value indicates that the LIF spectra is acquired from ischemic tissue, while a positive skewness will indicate normally perfused tissue.
  • the bottom of the central spectral valley is considered as the baseline for the definition of the main lobe as indicated in FIG. 16.
  • the intrinsic LIF of normal biological tissue will have a spectrum with a single peak resembling that of the main tissue fluorophores, collagen and elastin.
  • the intrinsic LIF develops a secondary peak or a hump at about 470-490 nm which is associated with the peak fluorescence emission of ⁇ ADH .
  • the appearance of this hump in an intrinsic LIF spectrum is a direct indication of oxygen deficiency resulting from hypoxia or ischemia.
  • this ⁇ ADH-related hump is not readily detectable in common LIF spectra because of an overlapping spurious hump created by an intensity dip associated with peak hemoglobin absorption at about 410 nm.
  • the intrinsic LIF spectrum of normal kidney does not exhibit the second hump created by the spectral valley associated with hemoglobin absorption.
  • the intrinsic fluorescence of hypoxic myocardium exhibits a secondary hump indicating high NADH concentration.
  • ischemia or hypoxia can be detected from a LIFAS-derived intrinsic LIF spectrum by assessing its NADH-related secondary hump either visually or through simple qualitative analysis.
  • the magnitude of the NADH hump will indicate the level of oxygen deficiency caused by hypoxia or ischemia while its absence indicate normal oxygenation.
  • ischemia or hypoxia detection techniques use predetermined ratios of spectral intensities at wavelengths associated with NADH, elastin and collagen to discriminate normal from abnormal tissue.
  • the magnitude of the intensity does not fully characterize spectral changes associated with ischemia or hypoxia. Instead, it is desirable to undertake spectral classification based on the shape of wavelength bands or the whole spectrum.
  • the introduction of the LIFAS methods and devices of the present invention enables the application of a new modeling approach for the measurement of ischemia and hypoxia.
  • the approach relies on methods of multivariate linear regression (MLR) , principle component regression (PCR) and the method of partial least squares (PLS) .
  • MLR multivariate linear regression
  • PCR principle component regression
  • PLS partial least squares
  • the MLR, PCR and the PLS models are trained with LIFA or absorbance spectra as their input and the concentration of both oxygenated and deoxygenated hemoglobin as their outputs.
  • the blood content (i.e. quantity of blood) in the tissue is determined by combining the concentrations of both oxygenated and deoxygenated hemoglobin.
  • the MLR, PCR and the PLS models are trained with LIFA spectra from normal, hypoxic or ischemic rabbit heart and kidney.
  • a model can be used to predict the concentrations of oxygenated and deoxygenated hemoglobin if given a LIFA spectrum measured from tissue with unknown oxygenation.
  • the presence and level of hypoxia can be determined by comparing the latter-predicted concentrations values to those known values previously measured from normal tissue. Hypoxic tissue have less oxygenated and more deoxygenated hemoglobin concentrations than normal tissue.
  • the presence and level of ischemia can be determined by combining the predicted concentrations to determine the total blood content and then comparing the total blood content to known values of blood content measured in normal tissue. Ischemic tissue will have a lower blood content than normally perfused tissue.
  • the PLS model was found to have the optimal accuracy in detecting the presence and level of ischemia and hypoxia .
  • a new mathematical classifier has been developed and applied to categorize spectral data for ischemia or hypoxia detection.
  • the recent multicriteria associative memories (MAM) technique is modified to perform as a data classifier. Similar to existing classifiers, the MAM requires initial training on a set of input-output data pairs. The training process of the MAM classifier involves the calculation of the weights matrix M( ⁇ ) from the input-output data set using the following learning rule :
  • the matrices "S” and “R” holds the input and output training vectors as their columns, respectively.
  • the superscripts ⁇ and “1 indicate matrix transpose and inversion, respectively, and "I” is the identity matrix.
  • the parameter ⁇ is initially set to 0.98; however, it can assume any value between 0 and 1 depending on the noise of the system.
  • the output "r" for an unknown input “s” can be readily calculated from the dot product:
  • the MAM classifier is initially trained with LIFA (or absorbance) spectra acquired from normal or ischemic tissue as the training inputs.
  • the corresponding normal or ischemic state can be encoded as, for example, "-1" or "1,” respectively and used as the training outputs. Therefore, the training LIFA spectra are placed as columns of the input matrix "S” while their corresponding state-coded values are arranged in the same order as elements of the output row vector "R.” The number of columns in "S” and elements in “R” are equal to the number of available training sets.
  • a trained MAM matrix can determine whether an unknown LIFA spectrum "s ?
  • the MAM classifier can be applied for the detection of hypoxia and the discrimination between normal, ischemic and hypoxic tissue. It should be apparent that common or intrinsic LIF spectra can replace LIFA spectra as the classifier input. In addition, this input can be an entire spectrum, a re-sampled version of a spectrum or a set of statistical parameters or features characterizing a spectrum. Similarly, actual ischemia or hypoxia levels can be used as the classifier outputs instead of the binary coded output values employed in the above demonstration. In this case a linear transfer function may be used to categorize the output "r" of the MAM classifier.
  • the MAM technique outperformed the commonly-used artificial neural network (ANN) classifier in accurately classifying LIF/LIFA spectra resulting from normal and ischemic tissue.
  • ANN artificial neural network
  • the superiority of the MAM classifier is most probably due to its insensitivity to spectral noise that might be present in LIF/LIFA spectra measured from biological systems.
  • the foregoing MAM classifier is currently applied to discriminate spectral data for the purpose of ischemia or hypoxia detection, it is understood that those skilled in the art may apply it in various ways for different classification purposes .
  • LIFAS devices and methods can be applied to tissue characterization, i.e., to differentiate between normal and diseased tissue, for tissue diagnostics and malignancy detection.
  • Current LIFS techniques use the intensity spectrum of modulated LIF to identify malignant (cancerous and pre-cancerous ) tissue and classify its type.
  • LIFAS techniques offer a unique tissue characterizing capability not offered by conventional LIFS, based upon measurement of the attenuation spectrum.
  • FIGS. 17(a)-(d) A simple demonstration of LIFAS diagnostic capability is shown in FIGS. 17(a)-(d). Although normal kidney and heart tissue are different in nature, their common LIF spectra, shown in FIGS. 17(a) and (b) are almost identical and, hence, are not so usefl for classifiation purposes. However, heart and kidney LIFA spectra, shown in FIG. 17(c) and d are different in terms of both shape and peak attenuation values. Thus, LIFAS techniques offer better tissue identification power than conventional LIFS techniques.
  • LIFAS methods and devices will include laser removal of decorative tattoos, detection of the in-vivo glucose level, assessment of the degree of burn trauma, detection of atherosclerotic plaque, angioplasty, measurement of acidity or alkalinity, pH measurement, the analysis of biochemical fluids, and the like.
  • measurement of the in vivo skin absorption using LIFAS methods and devices in accordance with the present invention can said in the selection of optimal laser wavelengths for removing tattoos of different colors.
  • LIFAS techniques can be used to determine absorbance from a hypodermic sample volume, the skin color and the depth of the tattoo dye can be more accurately characterized than in surface reflectance techniques.
  • burn injury assessment can be accomplished by using LIFAS techniques to measure the depth of burn by probing for the presence of blood perfusion at varying locations within the tissue.
  • LIFAS techniques can also be used to determine the absorbance or turbidity of a liquid in-situ without the necessity of extracting a sample for use in a spectrometer.
  • LIFAS devices and methods can be used to measure the absorbance and/or turbidity of materials and mixtures in medical, food, beverage, detergent, plastic, glass, oil, paint, textile, and semiconductor applications.
  • concentration of the pure components of the mixture can be determined from the absorbance spectrum using chemometric techniques such as multivariate regression (MLR) , partial least squares (PLS) or artificial neural networks described above.
  • MLR multivariate regression
  • PLS partial least squares
  • artificial neural networks described above.

Abstract

The Laser Induced Fluorescence Attenuation Spectroscopy method and apparatus include a source (311) adapted to emit modulated radiation that is directed at a sample volume in a sample (314) to produce return light from the sample, a first sensor (321), displaced by a first distance from the sample volume for monitoring the return light and generating a first signal indicative of the intensity of return light, a second sensor (322) displaced by a second distance from the sample volume for monitoring the return light and generating a second signal indicative of the intensity of return light, and a processor (323) adapted to process the first and second signals so as to determine the modulation of the sample. Methods and devices are well-suited for determining the wavelength-dependent attenuation of a sample and using the attenuation to restore the intrinsic laser induced fluorescence thereof, and can be used to determine the ischemic or hypoxic condition of biological tissue.

Description

METHOD AND DEVICES FOR LASER INDUCED FLUORESCENCE ATTENUATION SPECTROSCOPY (LIFAS)
BACKGROUND OF THE INVENTION
The present invention is directed to methods and devices for determining a spectroscopic characteristic of a sample utilizing laser induced fluorescence attenuation spectroscopy ("LIFAS"). More particularly, the invention is directed to methods and devices for measurement of the wavelength-dependent attenuation of the sample and subsequent restoration of the intrinsic laser induced fluorescence ("LIF") for phsyioloical monitoring, biological tissue characterization and biochemical analysis.
Conventionally, samples have been characterized by determining the attenuation and laser induced fluorescence ("LIF") . Once the attenuation and LIF of a sample has been determined, these spectroscopic properties can be utilized to determine a physical or physiological property of the sample . For example, the attenuation of a sample can be used to determine the concentration of a mixture components or turbidity of a fluid. Similarly, the LIF of a sample has been used in fields such as analytical chemistry, environmental monitoring, industrial inspection and medical diagnosis. In the medical field, for example, LIF spectroscopic techniques have been used for tissue characterization, malignant tumor identification, atherosclerotic plaque diagnosis, metabolism evaluation, and the like. Conventionally, the attenuation or the absorption of a sample is determined by placing the sample between a light source and a detector and measuring any reduction in the intensity of the light as it passes through the sample . In order to obtain a measurement having an acceptable signal-to-noise ratio using these conventional techniques, it is important that transmit the incident light with sufficient intensity. Thus, the thickness of the sample and the wavelength of the incident light are important factors affecting the reliability of the resulting measurement. Moreover, because it is necessary to place the sample between the light source and the detector, it is difficult to perform attenuation measurements on certain types of samples, such as living tissue.
More recently, fiber optic techniques have been developed for the measurement of attenuation in which an optical fiber is used to guide the incident light to illuminate a sample inside a small chamber at the tip of a probe. A reflector is placed on the opposite side of the chamber to reflect the incident light into a second fiber which is associated with a detector. Unfortunately, these techniques find limited application with materials, such as fluids, that can readily pass into the chamber in the tip of the probe .
Conventionally, laser induced fluorescence ("LIFS") spectroscopic techniques utilize various optical configurations in which a laser is directed at a sample using an optical fiber and the LIF from the sample is collected using a second optical fiber. Alternatively, the same fiber can be used for excitation of the sample and the collection of LIF. In either case, the LIF collected by the fiber is modulated by the sample, e.g. by the wavelength-dependent absorption and scattering of constituents of the sample. Therefore, existing LIFS methods are limited by the fact that the "intrinsic" or "true" fluorescence of the sample's fluorophores cannot be determined. Recent reports have suggested measuring the diffuse reflectance spectrum of the tissue as a means for correcting the intrinsic LIF using Monte-Carlo mathematical formulations. However, such correction methods are critically dependent on the backscattering characteristics of the tissue. Furthermore, backscattering does not account for the effects of absorption and scattering suffered by the intrinsic fluorescence prior to its measurement. In biological LIF techniques, lasers are used to cause fluorophores in the sample to emit fluorescence. The main fluorophores in normal biological tissue are tryptophan, collagen and elastin. Other fluorophores, such as NAD (nicotinamide adenine dinucleotide) and FAD (flavin adenine dinucleotide) , are also normally present, but at much lower concentrations. Under certain conditions, the contribution of the various fluorophores to the LIF can change. For example, during an ischemic or hypoxic event, the tissue is deprived of oxygen and anaerobic respiration takes place. Consequently, the weak fluorophore NAD will be converted into the strong fluorophore reduced nicotinamide adenine dinucleotide ("NADH") . As a result, the LIF collected from the sample will reflect an increased contribution from NADH. This change is typically observed as a rise in the intensity of the LIF spectrum in the region of peak NADH emission, from about 470 to 490 nm. Thus, the metabolic state of the tissue can be determined by measuring the relative change in LIF intensity at the wavelength of peak NADH emission as compared to the relative change of the LIF intensity of fluorophores that are normally present in the tissue, such as elastin or collagen.
Unfortunately, the LIF of biological tissue is heavily modulated in the 390-450 nm range by the peak absorption of the main tissue chromophore, hemoglobin. Thus, although the intrinsic LIF spectra of normal tissue should approximately resemble that of the pure fluorophore components of the tissue, the measured LIF spectra has a valley in the 400-450 nm region that is associated with the hemoglobin absorption. As a result, the measured LIF spectrum tissue appears to have a double peak instead of the single peak spectrum associated with the pure fluorophores of the tissue. Hence, the LIF spectrum of normal tissue begins to resemble the spectrum associated with tissue suffering hypoxia or ischemia, which makes it more difficult to identify tissue abnormalities . Furthermore, since the optical properties of biological tissue are influenced by its hemoglobin concentration, the measured LIF will vary with the level of blood perfusion throughout the cardiac cycle. The LIF of contractile tissue, such as the myocardium, is highly dependent on its state of contraction. Contraction increases the concentration of the fluorophore NADH and, hence, its contribution to tissue fluorescence. During contraction, however, blood is pumped out of the tissue, thereby reducing its hemoglobin concentration and, hence, light attenuation. Thus, a contracted myocardium retains less blood (i.e., a lower hemoglobin concentration) and, therefore, exhibits lower light absorption, than when relaxed.
Organs such as the brain, heart and kidney are the most sensitive to oxygen deficiency and can suffer permanent damage following an ischemic or hypoxic event . During open heart surgery, for example, continuous monitoring of kidney perfusion, i.e., ischemia, is required. Similarly, since the success of a transplantation surgery is highly dependent on the level of organ perfusion at harvest and during preservation of the tissue, continuous monitoring of the organ is typically required.
Ischemia and hypoxia are both conditions that deprive tissue of oxygen, leading to anaerobic metabolism and the accumulation of the metabolic coenzyme NADH. The coenzyme NADH is a fluorescent molecule. Therefore, ischemia and hypoxia can be indirectly detected using LIF techniques by sensing increased concentrations of NADH and interpreting its elevation as a sign of oxygen deficiency. A common indicator of oxygen deficiency is the ratio between the LIF intensity at wavelengths associated with the peak fluorescence emission of NADH, collagen and elastin. However, such methods have not been practically applied for the detection of ischemia because of several complications. First, these methods cannot determine whether the elevated NADH concentration is caused by ischemia, hypoxia or hypermetabolism. Second, scarred or fibrosed tissue would be detected as normal because of their low NADH concentration. Finally, the indicator ratios are calculated by normalizing the intensity of NADH peak fluorescence by that of collagen or elastin. Although the fluorescence of the structural proteins elastin and collagen does not vary with tissue oxygenation, the fluorescence with the site of measurement.
The intrinsic LIF of biological tissue have a single peak spectral profile resembling that of the pure structural proteins which are primarily elastin and collagen. However, this single peak profile is modulated by the attenuation of hemoglobin, especially about 410 nm, to yield a distorted, double-peak spectrum. The second spurious peak at about 470 nm results from the spectral valley created by heavy hemoglobin absorption at about 410 nm. Unfortunately, this second peak overlaps and obscures the peak fluorescence emission of NADH at about 470- 490 nm, which may impede ischemia detection techniques that are based on NADH concentration.
The methods and devices of the present invention will enable measurement of several LIF parameters that directly relate to the state of tissue perfusion and/or hemoglobin oxygenation. This offer superior accuracy over the currently available LIF techniques which detect ischemia and hypoxia indirectly by sensing an upsurge in NADH fluorescence. In particular, the methods and devices of the present invention can directly indicate the presence and the level of hypoxia or ischemia. Furthermore, the methods of the present invention utilize novel criteria for discrimination between normal and ischemic or hypoxic tissue.
It is readily apparent that existing LIFS techniques in medicine and industry are affected by modulations of the intrinsic LIF. Thus, there is need for methods and devices for determining the intrinsic laser induced fluorescence while eliminating or minimizing modulating influences in order to provide more accurate and complete characterization of a sample. In particular, there is a need for method and devices for characterization of biological tissue. The present invention addresses these and other needs .
SUMMARY OF THE INVENTION
The present invention is embodied in a system and related method for laser induced fluorescence attenuation spectroscopy ("LIFAS") in which the attenuation and intrinsic LIF of a sample can be determined. The LIFAS system employs a source, a first sensor, a second sensor and a processor. The source, preferably a laser, emits light to irradiate a sample volume in a sample so that the sample volume produces return light, which preferably includes laser induced fluorescence. The first sensor monitors the return light at a first distance from the sample volume and generates a plurality of signals representing the intensity of the return light in predetermined wavelength bands . The second sensor monitors the return light at a second distance from the sample volume and generates a plurality of signals representing the intensity of the return light, preferably over the same wavelength bands. Where the first and second distances are different, the processor can be used to determine the wavelength-dependent attenuation of the sample using the signals of both sensors. The measured attenuation will typically reflect the effects of both absorption and scattering by the sample. For maximum signal-to- noise ratio, it is preferred that the first and second detectors monitor return light from the sample volume at a location in proximity to the sample volume .
Once the wavelength-dependent light attenuation is determined, the attenuation can be used to restore the intrinsic LIF of the fluorophores of the sample. Once the attenuation and intrinsic fluorescence have been determined, these factors can be used in a variety of applications, including medical diagnosis. In the preferred embodiment, the attenuation and fluorescence are used for the detection of ischemia and hypoxia of biological tissue. Ischemia and hypoxia are detected by monitoring spectral changes in the intrinsic LIF to detect a rise in the concentration of NADH in the tissue. Since ischemia is caused by a decrease in the blood content of the tissue, ischemic tissue will have lower concentrations of hemoglobin. Consequently, in ischemic tissue, absorption by hemoglobin, especially in the 390-450 nm spectral band, will be reduced. Changes in the wavelength of peak light transmission, especially in the 450-500 nm band, can also be used to detect hemoglobin oxygenation and, hence, the presence of hypoxia or ischemia. Finally, multicriteria associative memories
(MAM) can be used as an attenuation or fluorescence spectral classifier.
Other features and advantages of the present invention will be apparent from the following description of the preferred embodiments, taken in conjunction with the accompanying drawings, which illustrate, by way of example, the principles of the invention.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 is a schematic diagram of a spectroscopic system in accordance with the invention;
FIG. 2 is a schematic diagram of a Laser Induced Fluorescence Attenuation Spectroscopy system ("LIFAS") in accordance with the present invention having an excitation waveguide and a first and second collection waveguides; FIG. 3 is a schematic diagram of a LIFAS system in accordance with the present invention having a first excitation-collection waveguide and a second collection only waveguide; FIG. 4 is schematic diagram of a LIFAS system for biomedical applications in which excitation radiation is used to induce fluorescence of tissue;
FIGS. 5(a) and (b) are end perspective views of a LIFAS probe having an optical fiber and an optical fiber bundle as the central waveguide ;
FIGS. 6(a) and (b) are partial perspective views of an electrical subsystem used to synchronize a LIFAS system with the electrical activity of tissue using electrodes integrated into the optical probe;
FIGS. 7(a) and (b) are schematic diagrams showing the relative positions of the action potential and electrodes integrated into the optical probe; and FIGS. 7(c) and (d) are the corresponding action potential timing diagrams; FIG. 8 is a perspective view of a probe incorporating a visible light source for probe positioning and a circular LED array for indicating the direction of contraction propagation;
FIGS. 9 (a) -(c) are partial perspective views of three LIFAS probes having waveguides arranged in different geometrical configurations adapted for different applications;
FIG. 10 is a schematic diagram of a biomedical LIFAS system in accordance with the invention in which a single optical detector is used to measure the return light from two collection fibers; FIG. 11 is a block diagram of the method for determining the attenuation and the intrinsic fluorescence of a sample;
FIG. 12 is a graph of the attenuation spectrum measured from normal and ischemic renal cortex of rabbit kidney using LIFAS devices and methods in accordance with the invention; FIG. 13 is a scatter plot of the fluorescence intensity at 480 nm acquired from hypoxic (+) , normal (o) and hyperoxic (x) tissue through excitation-collection and collection-only waveguides;
FIG. 14 is a graph of the intensity Ico(λ)c of the signal measured by a collection-only waveguide from normal, hyperoxic and hypoxic tissue; FIG. 15(a) is a graph of the modulated LIF spectra of normal and ischemic kidney, and FIG. 15(b) is a graph of the intrinsic LIF spectra of normal and ischemic kidney;
FIGS. 16(a) and (b) are graphs of typical modulated LIF spectra of normal and ischemic kidney, respectively, depicting the difference in the symmetry of the main lobe; and
FIGS. 17 (a) -(b) are graphs of the mean LIF intensity of live kidney and heart tissue and FIGS. 17 (c) - (d) are the corresponding LIFAS-derived attenuation spectra.
DESCRIPTION OF THE PREFERRED EMBODIMENTS
As shown in the exemplary drawings and, in particular, FIG. 1 thereof, the present invention is embodied in a spectroscopic system 110 and related method for measuring the attenuation and/or optical rotation caused by a sample 114. The spectroscopic system 110 shown in FIG. 1, includes a source 111 that produces radiation 112, which is directed at a sample volume 113 within the sample 114. The source 111 is preferably a laser and the radiation 112 is preferably monochromatic ultraviolet (UV) , visible or infrared (IR) radiation 112. Nevertheless, the source 111 can be selected to produce other types of radiation, such as broad-band or polarized radiation, useful for a particular application. The spectroscopic system 110 further includes a first sensor 116 displaced by a distance Zl from the sample volume 113, and a second sensor 118 displaced by a distance Z2 from the sample volume 113, which are used to monitor return radiation 120 from the sample 114. In the preferred embodiment, the return radiation 120 will include fluorescence of the flurophores of the sample 114.
The sensors 116 and 118 each include an aperature 116a and 118a, respectively, through which the return radiation 120 is observed and collected. The sensors 116 and 118 typically can only observe the events occurring within the volume defined by a solid angle emerging from the aperture of the sensor. This volume is known as the numerical aperture or the field of view of the sensor. Thus, first and second sensors 116 and 118 include numerical apertures 117 and 119, respectively, that are adapted to receive a portion of the return radiation 120 from the sample 114. The sensors 116 and 118 can be tilted at different angles Θx and Θ2 and selected to have different numerical apertures 117 and 119 so that the sensors 116 and 118 can selectively monitor return radiation 120 from all or part of the sample volume 113. The sensors 116 and 118 each generate a signal 124a and 125a, respectively, representing the intensity Icl (λ) and Ic2(λ) and/or polarization of the return radiation 120. Preferably, the signals 124a and 125a are generated at a plurality of wavelengths within predetermined wavelength bands. The signal 124a from the first sensor 116 and the signal 125a from the second sensor 118 are communicated by signal paths 124 and 125, respectively, to a processor 123. As discussed in additional detail, below, the processor 123 processes the signals 124a and 125a to determine a spectral characteristic of interest, such as the attenuation and/or optical rotation of the return radiation 120 caused by the sample 114.
To determine the attenuation of the return radiation 120 caused by the sample, the sensors 116 and 118 are positioned at non-equivalent distances Zl and Z2 from the sample volume 113. Preferably, the first and second sensors 116 and 118 will be positioned so that one of the sensors will be in the immediate proximity of the sample volume 113 while the other sensor is positioned at a location adjacent to the first sensor, but displaced slightly further from the sample volume 113. It has been found that this arrangement advantageously improves the signal-to-noise ratio and, hence, measurement accuracy of the spectroscopic system 110.
The attenuation of the return radiation 120 is dependent on the distance traveled by the return radiation 120 through the sample 114. Hence, the signal 124a measured by the first sensor 116 and the signal 125a measured by the second sensor 118 will suffer different attenuation where the distances Zl and Z2 from the sample volume 113 are not equivalent. The processor 123 can be used to process the signals 124a and 125a to determine the wavelength-dependent attenuation of the sample 114. The attenuation determined by the spectroscopic system 110 will reflect the effects of light absorption and scattering by the sample 114. Where the radiation 112 causes fluorophores in the sample 114 to fluorescence, the attenuation of the sample 114 can be used to determine the intrinsic fluorescence 129 of the fluorophores in the sample volume 113. The methods by which the attenuation and intrinsic LIF are determined are discussed in detail below.
The source 111, shown in FIG. 1, can be any radiation source, such as a laser or a lamp emitting excitation radiation 112 at a wavelength capable of interacting with the sample 114. The sensors 116 and 118 will preferably include a detector, which can be as simple as individual light-sensitive diodes with appropriate band pass filters, or more complicated sensors such as an optical spectrum analyzer. Preferably, the sensor is a suitable spectrograph or spectrometer equipped with a suitable sensor. Alternatively, the sensor can include a multispectral CCD camera. In the preferred embodiment, the source 111 is an XeCl excimer laser emitting monochromatic ultraviolet radiation at 308 nm. Each of the sensors 116 and 118 is a spectrograph (Model FF250, ARIES Inc., Concorde, MA) associated with a 1024 element intensified photo diode array (PDA) to image the resolved spectrum. Each PDA is connected to an optical multichannel analyzer (OMA III, EG&G Princeton Applied Research Corporation, Princeton, NJ) . The OMA reads the light spectrum imaged by the PDA to produce the signals 124a and 125a. A 335 nm longpass filter (Schott WG335) is placed in front of the aperture of each of the sensors 116 and 118 to remove any backscattered 308 nm excitation radiation. The processor 123 is a personal computer that is networked to each of the sensors 116 and 118 via the signal paths 124 and 125 to receive the signals 124a and 125a, respectively.
In other applications, such as measuring the optical rotation or anisotropy of a sample, it will be desirable to position the first and second sensors 116 and 118 at equivalent distances Zl and Z2 from the sample volume 113. Optical rotation is observed in optically active materials. An optically active material is characterized by a lack of symmetry in its molecular or crystalline structure which causes a rotation of the plane of polarization in incident-plane-polarized radiation. The extent to which the plane of polarization is rotated will typically vary from one optically active material to another. In addition, the extent of rotation may depend on the number of molecules in the path of the radiation, the wavelength of the radiation, and the temperature of the material. Anisotrophy, on the other hand, is caused by a selective response of the sample to radiation travelling in different directions. In certain biological samples, for example, anisotrophy can result from microscopic inhomogenetics in the tissue structure. Use of equivalent distances Zl and Z2 will minimize the contribution of the path- length-dependent attenuation to the overall attenuation measured by the system 110. Therefore, the optical rotation or anisotropy of the sample can be determined more easily.
The LIFA system 110 shown in FIG. 1 can be adapted to measure optical rotation by utilizing first and second sensors 116 and 118 which are adapted to measure the polarization-dependent intensity of the return radiation. In particular, the first sensor 116 can be adapted to measure a first optical angle φx yielding the maximum intensity of the first portion 128 of the return radiation 120. Meanwhile, the second sensor 118 can be adapted to measure a second optical angle φ2 yielding the maximum intensity of the second portion 130 of the return light. The optical rotation of the return light 120 will be given by the difference between the angles φx and φ2, provided that the system has been properly calibrated. The same sensor is used for determination of the attenuation of the sample will find utility for monitoring the optical rotation. These sensors can be adapted to such measurements by placing a rotatable polarizing filter at each of the apertures 116a and 118a of the first and second sensors 116 and 118, respectively.
An alternative embodiment of the present invention is shown in FIG. 2(a) . In this embodiment, the spectroscopic system 110 of FIG. 1 has been adapted as a Laser Induced Fluorescence Attenuation Spectroscopy ("LIFAS") system 210. In the LIFAS system 210, a source 211 emits laser radiation 212 at an intensity and a wavelength capable of inducing fluorescence of the sample 214. The laser radiation 212 is transmitted through an excitation waveguide 215 to a sample volume 213 within the sample 214 where the laser radiation 212 excites local fluorophores in the sample volume 213 to emit intrinsic fluorescence 229. The intrinsic fluorescence 229 of the fluorophores in the sample volume 213 is modulated, for example, by the absorption and scattering of the local chromophores (not shown) and scatterers (not shown) present in the sample 214, respectively.
Two collection waveguides 221 and 222 having apertures 221a and 222a and numerical aperatures 217 and 219 are disposed about the excitation waveguide 215. As shown in FIG. 2(b), the collection waveguides 221 and 222 may be positioned such that their apertures 221a and 222b are laterally displaced from the excitation waveguide 215 by the distances xl ' and x2 ' and/or axially displaced from the aperture 215a of the excitation waveguide 215 by the distances yl ' and y2 ' . Preferably, the lateral distances xl ' and x2 ' are small or zero. Meanwhile, the axial distances yl ' and y2 ' are preferably selected to be small and unequal, while one of the axial distances is preferably zero. Also, it is desirable to position the apertures 215a, 221a and 222a of the waveguides 215, 221 and 222 in close proximity to or in contact with the sample 214 during use of the LIFAS system 210, as shown in FIG. 2(a) .
An alternative configuration of the collection waveguides is shown in FIG. 2(c). In this configuration, the axial distances yl ' and y2 ' are both zero. Meanwhile, the lateral distances xl ' and x2 ' are selected to be small and unequal. The apertures 240a and 242a of the waveguides 240 and 242 are oblique such that the fields of view 244 and 246 are directed toward the sample volume 213 and to advantageously encompass the bulk of the sample volume 213. As shown in FIG. 2(c), the distances zl' and z2 ' are directed along the respective axes of the numerical aperatures 244 and 246 and extend from the surface of the apertures 240a and 242a to the point of intersection of the axes of the numerical aperatures 244 and 246, respectively.
The collection waveguide 221 collects a first portion 228 of the return light 220 and transmits the first portion 228 of the return light 220 to a first sensor 216. The first sensor 216 generates a first signal 224a, representing the intensity Icl(λ) of the first portion 228 of the return light 220 at a plurality of wavelengths within predetermined wavelength bands. Similarly, the collection waveguide 222 collects a second portion 230 of the return light 220 and transmits the second portion 230 of the return light 220 to the second sensor 218. The second sensor 218 generates a second signal 225a representing the intensity Ic2(λ) of the second portion 230 of the return light 220 at a plurality of wavelengths preferably within the same wavelengths bands monitored by the first sensor 216.
The processor 223 then processes the first and second signals 224a and 225a to determine the wavelength-dependent attenuation of the sample 214. As discussed in detail, below, once the attenuation is known, either of the signals 224a or 225a can be processed to minimize the effects of attenuation and determine the intrinsic LIF 229 of the fluorophores in the sample volume 213. Alternatively, if the sensors 216 and 218 are selected to monitor the polarization of the first portion 228 and the second portion 230 of the return light 220, the processor 223 can be used to determine the optical rotation of the return light 220 caused by the sample 214.
Preferably, the intensity and wavelength of the laser radiation 212 should be sufficient to create a sample volume 213 that is large enough to have some overlap with the numerical apertures 217 and 219 of the collection waveguides 221 and 222, respectively. The numerical apertures 217 and 219 can be selected to encompass all or parts of the sample volume 213. Furthermore, longpass filters are placed before the inputs of the sensors 216 and 218 to selectively block backscattered excitation radiation. In the preferred embodiment, the source 211 is an Xe-Cl excimer laser emitting 308 nm ultraviolet excitation radiation 212. The waveguides 215, 221 and 222 are advantageously comprised of optical fibers or optical fiber bundles, which can be integrated into a probe for ease of use and durability. The optical bundle and fibers are made of fused silica which is transparent to ultraviolet radiation. Specifically, a 1.4 mm diameter optical bundle is used as the excitation waveguide 215 while the collection waveguides 221 and 222 are 0.4 mm optical fibers disposed about the excitation bundle. In the preferred probe embodiment, the lateral range xl ' and x2 ' are equal to zero while the axial distance yl ' is about 0.6 mm and the axial distance y2 ' is about zero. Furthermore, the probe may be configured within, for example, the shaft of a hypodermic needle, so that the in-vivo physiological or pathological properties of biological tissue can be determined.
In the preferred embodiment, each of the sensors 216 and 218 is a spectrograph (Model FF250, ARIES Inc., Concorde, MA) associated with a 1024 element intensified photo diode array (PDA) . Each PDA is connected to an optical multichannel analyzer (OMA III, EG&G Princeton Applied Research Corporation, Princeton, NJ) which measures the intensity of the light spectrum imaged by the PDA and produces the signals 224a and 225a. The processor 223 is a personal computer that is networked to each of the sensors 216 and 218 via the signal paths 224 and 225 to receive the signals 224a and 225a, respectively.
The method of determining the attenuation and intrinsic fluorescence of a sample is better understood with reference to the block diagram shown in FIG. 11, which illustrates the main steps involved in determining the wavelength-dependent attenuation coefficient α(λ) and the intrinsic fluorescence Iτ(λ) of a sample in accordance with the current invention. In the embodiment shown in FIG. 2(a), the first and second portions 228 and 230 of the return light 220 experience different attenuation effects due to the unequal path lengths traversed by the return light 220 from the sample volume 213 to the apertures 221a and 222a of the collection waveguides 221 and 222. The first portion 228 of the return light 220 collected by the aperture 221a travels an additional path-length of {yl'-y2'} through the tissue as compared to the second portion 230 of the return light 220 which is collected by the aperture 222a. Hence, the first portion 228 of the return light 220 suffers more path-length-dependent attenuation as compared to the second portion 230 of the return light 220. Thus, the signals 224a and 225a representing the intensity Icl(λ) and Ic2(λ) at different wavelengths will exhibit differing levels of modulation caused by the attenuation of the sample 214.
In addition, the signals 224a and 225a will also exhibit wavelength-dependent modulations caused by the instrumental effects. The wavelength-dependent modulations due to the instrumental effects can be determined and, in turn, compensated for by conducting a calibration of the LIFAS system 210. System calibration can be performed using light from a standard lamp (Quartz Halogen Lamp, Model No. 63358, Oriel Instruments,
Stratford, CT) having a predetermined continuous spectrum to measure the wavelength-dependent instrumental effects of the LIFAS system 210. Once these instrumental effects are known, the processor 223 can be adapted to correct the measured intensities I(λ) and Ic2(λ) for modulations caused by the wavelength-dependent instrumental effects. The corrected intensities Icl(λ)c and Ic2(λ)c representing the intensity of the first and second portions 228 and 230 of the return light 220 at different wavelengths can then used to determine the attenuation coefficient α(λ) of the sample 214 as described below.
The regions ® and ©, of FIG. 2(a) may be at an effective range, symbolized as "R, " from which the collection waveguides 221 and 222 collect the majority of the first and second portions of return light 228 and 230, respectively. The effective range "R" will vary with the attenuation of the sample. However, the regions ® and (D, are geometrically symmetric with respect to the aperture 215a of the excitation waveguide 215 and, hence, have identical intensity of the intrinsic fluorescence 229 represented by Iτ(λ) . Furthermore, since the lateral and axial distances xl ' , x2 ' and yl ' , y2 ' are predetermined by the configuration of the probe (in the preferred embodiment xl'=x2', yl ' >y2 ' , y2'=0), the wavelength-dependent intensities Icl(λ)c and Ic2(λ)c can be described by the following equations:
Icl(λ)c = Iτ(λ) e-α(λ)-(R+yl,) (1)
Ic2(λ)c = Iτ(λ) e-α(λ)-(R+y2,) (2)
The attenuation coefficient α(λ) can be calculated independent of the value of "R" from (1) and (2) as follows:
α(λ) = {l/{y2'-yl'}} ln{ Icl (λ) C/Ic2 (λ) c} (3)
Where the difference {y2'-yl'} is a known constant, "e" is the natural exponential function and "In" is the natural logarithm. It will be appreciated by those of ordinary skill in the art that the natural exponential and logarithm can be replaced by the common exponential and logarithm to the base 10, respectively. Similarly, for the probe configuration in FIG. 2(c), the attenuation coefficient can be calculated as follows :
α(λ) = {l/{z2'-zl'}} ln{Icl(λ)c/Ic2(λ)c} (4)
Once the attenuation coefficient α(λ) is determined, the intrinsic fluorescence, Iτ(λ), can be restored from either of the signals Icl(λ)c or Ic2(λ)c (preferably Ic2 (λ) c where y2 ' « yl ' ) by assuming an average effective range "R" from which most of the intrinsic fluorescence is collected. For biological tissue, the constant "R" is approximately about 0.2 mm at 308 nm excitation radiation. Therefore, the intrinsic fluorescence Iτ(λ) can be obtained by substituting the measured Ic2(λ)c into equation (2) and solving for Iτ(λ) using the constant R and the known value y2 ' :
Iτ(λ) = Ic2(λ)c e α(λ)-(R+y2,) (5)
Whether the measured attenuation accounts for absorption and/or scattering is mainly determined by the wavelength band of interest and the nature of the sample. The optical properties of biological tissue and the effects of tissue on LIF are greatly different for the wavelengths below and above approximately 600 nm. Below about 600 nm, the optical attenuation of biological tissue is primarily due to absorption and, hence, the attenuation coefficient α(λ) will represent absorptivity a (λ) . Absorptivity is a property of a substance, while absorbance is a property of a particular sample of a substance. Therefore, absorbance will vary with the concentration of the substance (e.g. hemoglobin) and geometry of the tip of the probe. Thus, for samples such as biological tissue where the attenuation of the sample is primarily due to absorption, the absorbance A(λ) and the percent transmittance %T (λ) of the sample can be calculated as follows:
A (λ) = log { lc2 (λ) c/Icl (λ) c } ( 6 )
%T (λ) = 100- { Icl (λ) c/Ic2 (λ) c} ( 7 )
In an alternative embodiment of the LIFAS system 310, shown in FIG. 3(a), the source 311 emits laser radiation 312 at a wavelength and intensity capable of inducing fluorescence of the sample 314. The laser radiation 312 is reflected by a dichroic mirror 326 into an excitation-collection waveguide 321, which transmits the laser radiation 312 to the sample volume 313 where the laser radiation 312 excites local fluorophores to emit intrinsic fluorescence 329. Furthermore, the intensity of the laser 312 should be sufficient to create a sample volume 313 that overlaps with the numerical aperture 319 of the collection-only waveguide 322. The dimensions of the sample volume 313 will also depend on the numerical aperture of the excitation-collection waveguide 321, on the wavelength and intensity of the excitation radiation 312 and on the optical properties of the sample 314. The intrinsic fluorescence 329 is modulated, for example, by the absorption and scattering of the local chromophores (not shown) and scatterers (not shown) of the sample 314.
The excitation-collection waveguide 321 collects a first portion 328 of the return light 320 directly from the sample volume 313. The first portion 328 of the return light 320 is transmitted through the dichroic mirror 326 to the first sensor 316. The first sensor 316 generates a first signal 324a representing the intensity Ixc(λ) of the first portion 328 of the return light 320 at a plurality of wavelengths within a predetermined wavelength band.
As shown in FIG. 3(a), the collection-only waveguide 322 may be positioned such that the aperture 322a is laterally displaced from the excitation-collection waveguide 321 by the distance x3 and axially displaced from the aperture 321a of the excitation- collection waveguide 321 by the range y3. Preferably, the lateral distance x3 is zero while the axial distance y3 is non-zero. Also, the apertures 321a and 322a of the waveguides 321 and 322 are preferably positioned in close proximity to or in contact with the sample 314 during use of the LIFAS system 310, as shown in FIG. 3(a). Meanwhile, the numerical aperture 319 of the collection-only waveguide 322 is selected to include at least a portion of the sample volume 313.
The collection-only waveguide 322 collects a second portion
330 of the return light 320 which is transmitted to a second sensor 318. The second sensor 318 generates a second signal 325a representing the intensity Ico(λ) of the second portion 330 of the return light 320 at a plurality of wavelengths preferably within the same wavelength bands as the signal 324a generated by the first sensor 316. Furthermore, a longpass filter is placed in front of the aperture of each of the sensors 316 and 318 to selectively block backscattered excitation radiation. In the embodiment shown in FIG. 3(a), the first and second portions 328 and 330 of the return light 320 experience different attenuation effects due to the unequal path-lengths traversed by the return light 320 from the sample volume 313 to the apertures 321a and 322a of the waveguides 321 and 322, respectively. The second portion 330 of the return light 220 collected by the aperture 322a travels an additional path-length through the tissue as compared to the first portion 328 of the return light 320 which is collected by the aperture 321a directly from the sample volume 313. Hence, the first portion 328 of the return light 320 suffers less path-length-dependent attenuation as compared to the second portion 330 of the return light 320. Thus, the signals 324a and 325a representing intensity Ixc(λ) and Ico(λ) at different wavelengths will exhibit different levels of modulation caused by the sample 314. The signals 324a and 325a will also exhibit wavelength- dependent modulations caused by the instrumental effects. The wavelength-dependent modulations due to instrumental effects can be determined and, in turn, compensated for by conducting a calibration of the LIFAS system 310. System calibration is performed using light from a standard lamp (Quartz Halogen Lamp, Model No. 63358, Oriel Instruments, Stratford, CT) having a predetermined continuous spectrum to measure the wavelength- dependent instrumental effects of the LIFAS system 310. Once these instrumental effects are known, the processor 323 can be adapted to correct the measured intensities Ixc(λ) and Ico(λ) for modulations caused by the wavelength-dependent instrumental effects. The corrected intensities Ixc(λ)c and Ico(λ)c representing the intensity of the first and second portions 328 and 330 of the return light 320 at different wavelengths can then be used by the processor 323 to determine the wavelength-dependent attenuation α(λ) of the sample 314. As discussed in detail, below, once the attenuation is known, either of the signals 324a or 325a, preferably 324a, can be corrected for the effects of attenuation to restore the intrinsic LIF 329 of the fluorophores in the sample volume 313.
In the preferred embodiment, the source 311 is an Xe-Cl excimer laser emitting ultraviolet excitation radiation at a wavelength of 308 nm. The waveguides 321 and 322 are advantageously comprised of optical fibers or optical fiber bundles, which can be integrated into a probe for ease of use and durability. A 1.4 mm diameter optical bundle and a 0. mm optical fiber are used as the excitation-collection and the collection- only waveguides, respectively. Preferably, the collection-only waveguide is a plurality of 0.4 mm optical fibers disposed about the periphery of the excitation-collection waveguide. The optical bundle and fibers are made of fused silica which is transparent to the 308 nm ultraviolet radiation. Furthermore, the probe may be configured within, for example, the shaft of a hypodermic needle, so that the in-vivo physiological or pathological properties of biological tissue can be determined. Each of the sensors 316 and 318 is a spectrograph (Model FF250, ARIES Inc., Concorde, MA) associated with a 1024 element intensified photo diode array (PDA) to image the resolved spectrum. Each PDA is connected to an optical multichannel analyzer (OMA III, EG&G Princeton Applied Research Corporation, Princeton, NJ) which measures the intensity of the light spectrum imaged by the PDA and produce the signals 324a and 325a. The processor 323 is a personal computer that is networked to each of the sensors 316 and 318 via the signal paths 324 and 325 to receive the signals 324a and 325a, respectively.
The method of determining the attenuation coefficient α(λ) and the intrinsic fluorescence Iτ(λ) of a sample using the embodiment of FIG. 3(a) in accordance with the current invention is as follows. In the embodiment shown in FIG. 3(a), "D" represents the effective range, from which the collection waveguide 321 collects a majority of the portion 328 of the return light 320. The portion 328 of the return light 320 is collected directly from the sample volume 313 by the excitation-collection waveguide 321. Therefore, the wavelength-dependent intensity Ixc(λ)c of the portion 328 of the return light 320 collected by the excitation-collection waveguide 321 will be substantially similar to the wavelength-dependent intensity of the return light 320, represented as I0(λ). However, the return light 320 with the intensity I0(λ) will suffer additional wavelength-dependent attenuation as it travels the extra path-length to reach the aperture 322a and is collected as the second portion 330 of the return light 320 with the intensity Ico(λ)c. The lateral and axial distances x3 and y3 will be predetermined by the configuration of the waveguides 321 and 322. In the preferred embodiment, the lateral distance x3=0 and the axial distance y3>0. Thus, the wavelength-dependent intensity Ico(λ)c can be approximated by the following equations :
Ixc(λ)c - I0(λ) = Iτ(λ) e-α(λ»-D (8)
Ico(λ)c - I0(λ) e-α(λ'-y3 * xc(λ)c e-α(λ)-y3 (9)
α(λ) = U/y3} ln{lxc(λ)c/lco(λ)c} (10)
Similarly, for the alternative probe configuration shown in FIG. 3(b), where the lateral distance x3'>0 and the axial distance y3'=0, the attenuation coefficient can be approximated as follows:
α(λ) ={l/x3'} ln{Ixc(λ)c/Ico(λ)c} (11)
Once the attenuation coefficient α(λ) is determined, the intrinsic fluorescence, Iτ(λ), can be restored from either of the signals Ixc(λ)c or Ico(λ)c, preferably Ixc(λ)c, by assuming an average effective range "D" from which most of the intrinsic fluorescence is collected. For biological tissue, the constant "D" is approximately about 0.2 mm at 308 nm excitation radiation. By substituting the measured Ixc(λ)° into equation (7) and solving for Iτ(λ) :
Iτ(λ) = Ixc(λ)c eα(λ)-D (12)
As discussed in connection with the previous embodiment, the measured attenuation may account for absorption and/or scattering depending on the wavelength band of interest and the nature of the sample. Below about 600 nm, the optical attenuation of biological tissue is primarily due to absorption and, hence, the attenuation coefficient α(λ) will represent absorptivity a (λ) . Also, the absorbance A(λ) and the percent transmittance %T (λ) of such samples can be calculated as follows:
A(λ) = log{lxc(λ)c/Ico(λ)c} (13)
%T(λ) = {Ico(λ)c/Ixc(λ)c} 100 (14)
In another alternative embodiment shown in FIG. 4, a LIFAS system 410 in accordance with the present invention has been adapted for biomedical applications. In this particular embodiment, the LIFAS system 410 has been adapted to determine the optical attenuation of biological tissue. The laser 411 emits radiation 412 at a wavelength capable of exciting the tissue 414 to emit fluorescence. The radiation 412 is directed through an iris 440 at a dichroic mirror 442 which reflects the radiation 412 onto a lens 444 which focuses the radiation 412 onto the proximal tip 445 of an optical fiber 446. The adjustable iris 440 is advantageously used to reduce the energy of the radiation 412. Alternatively, the adjustable iris 440 can be replaced by any suitable attenuator. The probe 448 includes a central optical fiber 446 that is used as the excitation-collection fiber and peripheral optical fibers 450a-h are used as the collection-only fibers. The distal end of the optical fibers 446 and 450a-h are incorporated into the optical probe 448. The aperture 448a the optical fiber probe 448 is placed in proximity to the tissue 414 so that the aperture 446a of the excitation-collection fiber 446 and apertures 451a-h of the collection-only fibers 450a-h are in contact with the tissue 414. As shown in a partial perspective view in FIG. 5(a), the optical fiber probe 448 includes a central optical fiber 446 and a plurality of optical fibers 450a-h disposed about the periphery of the central optical fiber 446. The apertures 451a-h of the distal ends of the collection-only fibers 450a-h are axially displaced by a small distance y3 with respect to the aperture 446a of the excitation-collection fiber 446. The return light 420 collected by apertures 451a-h of the collection-only fibers 450a-h pool into the aperture 418a of the sensor 418. It will be appreciated by those in the art that the optical fibers 446 and 450a-h can advantageously be replaced by optical fiber bundles in order to obtain greater flexibility and durability. For example, as shown in FIG. 5(b), the central optical fiber 446 can be replaced with an optical fiber bundle 454.
The excitation radiation 412 is transmitted through the optical fiber 446 to the tissue 414 to induce intrinsic fluorescence of the fluorophores of the tissue 414. The intrinsic fluorescence is modulated, for example, by the chromophores and/or scatterers of the tissue 414. A first portion 428 of the return light 420 is collected by the optical fiber 446 from the tissue volume that is directly irradiated by the excitation radiation 412 and transmitted through the optical fiber 446 to a first lens 444 where the return light is directed through the dichroic mirror 442 and then focused by a second lens 445 onto the aperture 416a of a first sensor 416. Similarly, the collection-only optical fibers 450a-h collect a second portion 430 of the return light 420 and transmit the second portion 430 of the return light 420 to the second sensor 418. Preferably, longpass filters are placed in front of the apertures 416a and 418a of the sensors 416 and 418 to selectively block backscattered excitation radiation. A first signal 424a and a second signal 425a representing the intensity of the first and second portions 428 and 430, respectively, of the return light 420 are generated by the first and second sensors 416 and 418 and transmitted via signal paths 424 and 425 to the processor 423. The processor 423 uses the first and second signals 424a and 425a generated by the detectors 416 and 418 to determine the wavelength-dependent attenuation of the sample 414 using equations (8), (9) and (10) as described in the previous embodiment .
In a particularly preferred embodiment of the LIFAS probe 448 shown in FIG. 8, an illumination source 490 emitting visible light 492 is mounted on the probe 448 to act as a spotlight for the operator. Because room illumination can contaminate the spectral measurements of the system 410 by adding background light, use of the illumination source 490 will allow the operator to see and accurately position the probe 448 under low-light conditions. The illumination source 490 is configured to illuminate the sample at all times, except when the LIFAS system is monitoring return light from the sample 414.
The biological electrical signal arising in nerves or contractile tissue, such as muscle, is known as the "action potential" and is caused by sudden changes in the ion conductivity of the cell membrane. The occurrence of an action potential in contractile tissue initiates a contraction. For example, in cardiac tissue, the action potential propagates and spreads in a wave-like manner to induce a local myocardial contraction wherever it travels. An action potential propagating in the tissue local to the aperture 448a of the probe 448 can be detected by the electrode
464 which is incorporated into the probe 448 as shown, for example, in FIG 6(a) . Voltage alternations caused by the occurrence of the action potential are picked up by the electrode 464 in reference to the common electrode 466 and are transmitted to the amplifier 460. The common electrode 466 provides the electrical ground for the amplifier 460 by maintaining contact with the tissue of interest 414 or the whole body. As discussed in connection with FIG. 7, below, the amplified action potential 468 is transmitted to the processor 423 to trigger the acquisition process of the LIFAS system 410 at a pre-selected phase of the tissue contraction or of the cardiac cycle, whichever is applicable .
In an alternative probe arrangement, a plurality of electrodes or fibers with a conductive coating can be distributed circumferentially about the tip of the optical fiber probe 448. For example, as shown in FIG. 6(b), the probe 448 can be equipped with three electrodes 470, 472 and 474 arranged in a triangular configuration. The action potentials measured by each of the electrodes 470, 472 and 474 are amplified through separate channels of the amplifier 460 and transmitted to the processor 423. As illustrated in FIG. 7, the processor 423 processes the received signals to determine the direction of propagation of the contraction vector 462. In particular, the processor detects the phase lead/lag between the action potentials collected by the electrodes 470, 472 and 474 to determine the orientation of the contraction vector 462 with respect to the location of the electrodes 470, 472 and 474.
For example, the contraction vector 462 shown in FIG. 7(a) is propagating from the tissue site 476a to the site 478a and, hence, as shown in FIG. 7(c), the action potential 474a arrives before the action potential 472a which in turn arrives before the action potential 470a. Moreover, the phase difference or time delay between a pair of action potentials indicates how the contraction vector 462 is centered between the location of the corresponding pair of electrodes. For example, as shown in FIG 7(b), the contraction vector 462 propagates from the tissue site 476b to the site 478b. As a result, the corresponding time of arrival of action potentials 470b, 472b and 474b, as shown in FIG. 7(d), will vary. The processor 423 processes the signals and indicates the direction of the propagation of the contraction to the system operator. The direction of propagation can be indicated, for example, by a circular array 496 of light emitting diodes (LED) 498 mounted cirumferentially on the probe 448, as shown in FIG. 8. The processor 423 transmits a signal to the LED array 496 so that, for example, only the LED element pointing in the direction of contraction propagation would glow.
It will be appreciated that the amplifier 460 can be replaced by any device that can measure the electrical activity of biological tissue such as a differential amplifier, an electrocardiogram (ECG) , an electromyogram (EMG) , an electroencephalogram (EEG) , depending on the LIFAS application. Furthermore, it will be appreciated that optical fibers with a metallic or electrically conductive coating can be used in place of one or all of the electrodes 464, 470, 472 or 474 to measure the action potential of the tissue. It should be noted that, conventional ECG is generally not suitable for triggering the acquisition of LIFS or LIFAS systems, since it does not accurately indicate the instantaneous state of myocardial contraction at the sample volume. However, customary ECG using limb or chest leads can be used to trigger data acquisition of the LIFAS system 410 where the sample 414 is non-contractile tissue.
In the LIFAS system 410 shown in FIG. 4, the light source 411 is preferably a lamp or a laser that emits ultraviolet, visible or infrared radiation. In the preferred embodiment, the source 411 is an XeCl excimer laser emitting pulses of ultraviolet excitation radiation at 308 nm. Where ultraviolet radiation is used, it is advisable that the optical components used in the acquisition system be made of synthetic quartz (fused silica) to ensures maximal ultraviolet transmission and minimal instrumental fluorescence. Alternatively, a nitrogen laser, a helium-cadmium laser, a frequency-multiplied laser, a solid-state laser, an arc lamp or a light-emitting diode can be used as the light source 411. The energy of the excitation light 412 is typically between 0.001-lOm Joules. However, it will be appreciated that the selected energy level should be low enough to avoid tissue ablation and/or photobleaching while still being adequate to produce detectable LIF. In the preferred embodiment, the sensors 416 and 418 are each comprised of a spectrograph (Model FF250, ARIES Inc., Concorde, MA) associated with a 1024 element intensified photo diode array (PDA) detector. An optional low fluorescence, long-pass filter (not shown) with a cutoff wavelength above 308 nm, preferably 335 nm (Schott WG335) , is placed before the entrance slit of each spectrograph to selectively block any backscattered excitation radiation from reaching the sensors 416 and 418. The entrance slit of the spectrograph preferably has a width of 100 micrometers. The spectrograph uses a 150 lines per millimeter diffraction grating to disperse the incoming return light 420 into its spectral components.
The spectrum formed by the spectrograph is imaged by a detector, preferably an intensified linear photodiode array (Model 1420, EG&G Princeton Applied Research Corporation, Princeton, NJ) facing the output port of the spectrograph. The photodiode array generates a plurality of electrical signals representing the intensity of the return light 420 at wavelengths within predetermined wavelength bands. Alternatively, the sensors can be constructed of any suitable materials, such as individual light- sensitive diodes with appropriate band-pass filters for the analysis of spectral bands of the return light or an optical spectrum analyzer ("OSA") for analysis of a broader spectrum. Selection of the return light monitoring device will depend on a variety of factors, including cost, accuracy, resolution, and whether the user is interested in monitoring a single wavelength, a wavelength band or an entire spectrum.
Although in the preferred embodiments shown in FIGS. 4 and 5, the optical fiber probe includes a central excitation-collection optical fiber or optical fiber bundle with a plurality of collection-only optical fibers disposed around its periphery, it will be appreciated by those of ordinary skill in the art that the probe can take many forms. Furthermore, it will be appreciated that the central optical fiber can be used as the collection-only waveguide while all or some of the peripheral fibers can be used for excitation-collection or collection-only. The latter arrangement is preferred when testing highly-attenuating samples to achieve a better signal-to-noise ratio.
FIG. 9 shows three alternative geometrical configurations of the collection-only optical fibers 950a-h about the excitation-collection waveguide 946. In these embodiments, it is desirable to couple each of the collection-only waveguides 950a-h to a separate sensor so that the intensity of each portion of the return light collected by each fiber can be monitored. In FIG. 9(a), the collection-only waveguides 950a-h are arranged about the excitation-collection waveguide 946 so that their apertures have a helical configuration. Because the aperture of each successive collection-only waveguide is shifted axially away from the aperture 947 of the excitation-collection waveguide 946, the return light collected by each of the collection-only waveguides 950a-h will be attenuated in varying degrees. Use of a probe arrangement having a plurality of collection distances will be useful in measuring the polarization and/or the attenuation of especially, a sample having a higher sensitivity to attenuation due to absorption. Furthermore, a probe incorporating a plurality of collection distances have application to a larger variety of samples. For example, where the sample is highly attenuating, the collection- only waveguides having apertures close to the excitation site can be used to collect the return light. Where the sample is lightly attenuating, the return light collected by the waveguides having apertures that are further from the excitation site will be useful in determining the attenuation.
In FIG. 9(b), the collection-only waveguides 950a-c are displaced laterally with respect to the excitation-collection waveguide 946. Such a probe configuration will be useful in measuring the polarization and/or the attenuation of the sample where the sample has a higher sensitivity to attenuation due to scattering. The return light collected by the waveguide 950c will be useful in measuring attenuation of a lightly attenuating sample. On the other hand, the return light measured by the closest waveguide 950a will be useful in measuring the attenuation of a heavily-attenuating sample.
In FIG. 9(c), the collection-only waveguides 950a-c are both axially and laterally displaced with respect to the excitation-collection waveguide 946. This configuration combines the advantages of both of the aforementioned configurations shown in FIGS. 9(a) and 9(b).
In an alternative embodiment of the LIFAS system of FIG. 4, shown in FIG. 10, a single sensor 1016 and an associated optical multiplexer 1080 are utilized. The multiplexer 1080 is used to switch the input of the sensor 1016 between the excitation- collection optical path (1046, 1044, 1042, 1049, 1046') and the collection-only optical path (1050) such that the return light from each pathway is measured sequentially. The processor 1023 sends trigger signals to the source 1011, the sensor 1016 and the optical multiplexer 1080 to synchronize their actions. If the source 1011 is a pulsed laser, two or more radiation pulses are typically required to acquire a single attenuation measurement using the multiplexed system 1010. A single laser pulse can be used if the laser pulse lasts long enough to sustain the emission of return light 1020 during the minimum period of time required by the optical multiplexer 1080 and associated sensor 1016 to acquire the spectral measurements from both the excitation-collection and the collection only optical paths. The preferred embodiment of the LIFAS system 1010 is similar to that of 410, except that the system 1010 utilizes an electromagnetic dual port shutter as the optical multiplexer 1080 associated with a single sensor 1016 in a configuration where the portion 1028 and the portion 1030 of the return light 1020 are measured sequentially.
Diagnosis of Hypoxia and Ischemia
The LIFAS methods and devices of the present invention can be used advantageously for the in-vivo diagnosis of hypoxia and ischemia of biological tissue. Hypoxia is a deficiency in the amount of oxygen reaching the tissue, e.g., due to pneumonia, whereas, ischemia is a localized reduction in arterial blood perfusion, e . g. , due to a narrowing of arteries by spasm or disease. Ischemia can also result from hemorrhage of an arterial wound or during surgical procedure that temporarily interrupts the blood flow to a body region. The present invention describes new criteria and methods for the discrimination between normal, ischemic and hypoxic biological tissue, including, in particular renal and myocardial tissue, as follows.
Utilizing LIFAS methods and devices, it has been found that ischemic (or hypoxic) tissue exhibits a lower laser induced fluorescence attenuation ("LIFA") than normal tissue of the same type. Since LIFA is an absolute quantity, its magnitude can be directly compared with predetermined standard values. Similarly, in absorption-dominant media, the absorbance or percent transmittance can also be utilized. It has been found that, although the LIFA of ischemic tissue is lower than the LIFA of normal tissue over all wavelengths, the transition is most prominent between 350 and 450 nm.
The LIFAS-derived LIFA spectra of normal and ischemic rabbit kidney are shown in FIG. 12. The LIFA spectra shown in FIG. 12 are acquired using a LIFAS system employing 308 nm excitation radiation produced by an XeCl excimer laser. This LIFAS system uses a 335 nm longpass filter (Schott WG335) to cutoff backscattered excitation radiation form the collected return light. Hence, for this particular LIFAS system the LIFA values below 350 nm are not reliable. For biological tissue, the LIFA values in the wavelength band about 480 nm have the highest signal-to-noise ratio and hence measurement accuracy. As shown in FIG. 12, the LIFA of ischemic tissue is lower than the LIFA of normal tissue over the entire spectrum and is particularly low in the region from 350 to 450 nm.
As demonstrated in FIG. 12, the LIFA, absorbance or percent transmittance at a predetermined wavelength or wavelength bands can be used for the detection of ischemia or hypoxia. Furthermore, predictive models, spectral recognition techniques and associated classifiers can be applied to identify whether a given LIFA, absorbance or percent transmittance spectrum has been acquired from normal, ischemic or hypoxic tissue. The classifiers can be initially trained with LIFA, at a predetermined wavelength or wavelength bands acquired from tissue with a known state of perfusion or oxygenation.
Another parameter found to be useful in the classification of normal, ischemic and hypoxic tissue, is the intensity of return light from a pair of LIFAS collection pathways (i.e. [Icl(λ)c,Ic2(λ)c] or [I λ) c, I clλ)c] for the LIFAS embodiments described above.) For example, FIG. 13 shows the [Ixc(λ) c, Ico(λ) c] pair at λ=480 nm, symbolized as [Ixc (480) , Ico ( 480) ] , measured from hyper-oxygenated (x) , normal (o) and oxygen deficient (+) rabbit kidney. The [Ixc (480) c, Ico (480) c] from normal and oxygen deficient tissue tend to cluster in two linearly separable regions of the two dimensional Ixc (λ) c-Ico (λ) c space. Thus, a simple linear or nonlinear classifier function can be trained on a set of [Ixc (λ) c, Ico (λ) c] pairs measured using a LIFAS system from normal, ischemic and hypoxic tissue. Other classifiers such as artificial neural networks (ANN) are also being used. The trained classifier function can then be used to classify an unknown [Ixc (λ) c, Ico (λ) c] pair as normal, ischemic or hypoxic. A "nearest neighbor" (NN) classifier has been found to perform satisfactorily. The NN classifier checks the proximity of an unknown [Ixc (480) c, Ico (480) c] pair to clusters of predetermined [Ixc (480) c, Ico (480) c] pairs measured from known normal, ischemic and hypoxic tissue. Other classifiers such as artificial neural networks (ANN) can also be utilized. For myocardial and renal tissue it has been found that it is preferable to use [Ixc (λ) c, Icoc) ] measured at 480 nm, to optimize signal-to-noise ratio. However, [Ixc (λ) c, Ico (λ) c] at other single or multiple pre-selected wavelengths can also be used.
An additional parameter for the classification of normal, ischemic and hypoxic tissue, is the wavelength of the peak transmittance of the tissue, symbolized hereafter as λmax_τ, especially in the 450-500 nm band. An alternative to λmax_τ is the wavelength of the peak Ico(λ)c in the 450-500 nm band, symbolized hereafter as λ,„ax_co. Both λmax_τ and „ax_co shift towards shorter wavelengths as the hemoglobin in the tissue becomes deoxygenated . For example, FIG. 14 shows Ico(λ)c spectra that are acquired using the LIFAS system shown in FIG. 10 employing 308 nm excitation radiation produced by and XeCl excimer laser. It should be noted that the λmax_co of normal tissue shifts to a shorter wavelength as the tissue becomes hypoxic; whereas the λmaχ-co °f normal tissue shifts to a longer wavelength as the tissue becomes hyperoxic. Specifically, λmax_co varies between about 480 and 500 nm as blood or hemoglobin oxygenation varies between deoxygenated to oxygenated, respectively. A separation border can be identified at about 489.5 nm to separate λmax_co of normal tissue (peaks above 489.5 nm) from hypoxic/ischemic tissue (peaks below 489.5 nm) . A simple classifier can be trained to identify tissue as hypoxic if its λraax_co is below 489.5, and vice versa. The degree of hypoxia is determined from the magnitude of the shift in λmax.c0 from the normal value, the smaller the shift the subtle the hypoxia.
The presence of renal or myocardial ischemia can be detected from the shape of the main lobe of the common LIF (e.g. Ixc(λ)c) spectrum in the wavelength band 350-450 nm. The common LIF can be acquired via an excitation-collection waveguide of a LIFAS or a conventional LIFS system. For example, FIGS. 16(a) and (b) show typical LIF spectra acquired from normal and ischemic rabbit kidneys at an excitation wavelength of 308 nm. As shown in FIG. 16(b), the shape of the main lobe of the LIF acquired from normal tissue is skewed to the right (a positive skewness value) .
However, the shape of the main lobe of the LIF acquired from ischemic tissue is almost symmetric (a very small skewness value) .
Skewness can be measured by a single parameter which indicates the degree of asymmetry of a lobe or curve around its mean value. For a symmetrical lobe the skewness is zero, however for an asymmetrical lobe the skewness can be either positive or negative depending on the shape. The skewness "S" is given by:
N x)J (15)
N λ=l
- ∑ Xχ (16)
" λ=ι
where x is the intensity of the fluorescence at the wavelength λ,
X is the mean intensity of the lobe, λ is the wavelength and Ν is the number of wavelength measurements in the lobe.
Therefore, tissue ischemia can be detected by monitoring the skewness of the main lobe of a common (i.e. modulated) LIF acquired using an excitation-collection fiber from the tissue. A zero or negative skewness value indicates that the LIF spectra is acquired from ischemic tissue, while a positive skewness will indicate normally perfused tissue. The bottom of the central spectral valley is considered as the baseline for the definition of the main lobe as indicated in FIG. 16.
The intrinsic LIF of normal biological tissue will have a spectrum with a single peak resembling that of the main tissue fluorophores, collagen and elastin. However, in the event of ischemia or hypoxia the intrinsic LIF develops a secondary peak or a hump at about 470-490 nm which is associated with the peak fluorescence emission of ΝADH . The appearance of this hump in an intrinsic LIF spectrum is a direct indication of oxygen deficiency resulting from hypoxia or ischemia. Unfortunately, this ΝADH-related hump is not readily detectable in common LIF spectra because of an overlapping spurious hump created by an intensity dip associated with peak hemoglobin absorption at about 410 nm. For example, in common and intrinsic LIF spectrum of normal and ischemic rabbit myocardium shown in FIG. 15(a) and (b) , respectively, the intrinsic LIF spectrum of normal kidney does not exhibit the second hump created by the spectral valley associated with hemoglobin absorption. To the contrary, the intrinsic fluorescence of hypoxic myocardium exhibits a secondary hump indicating high NADH concentration. Accordingly, ischemia or hypoxia can be detected from a LIFAS-derived intrinsic LIF spectrum by assessing its NADH-related secondary hump either visually or through simple qualitative analysis. The magnitude of the NADH hump will indicate the level of oxygen deficiency caused by hypoxia or ischemia while its absence indicate normal oxygenation.
Classification using Chemometric Models
Current ischemia or hypoxia detection techniques use predetermined ratios of spectral intensities at wavelengths associated with NADH, elastin and collagen to discriminate normal from abnormal tissue. However, the magnitude of the intensity does not fully characterize spectral changes associated with ischemia or hypoxia. Instead, it is desirable to undertake spectral classification based on the shape of wavelength bands or the whole spectrum.
The introduction of the LIFAS methods and devices of the present invention enables the application of a new modeling approach for the measurement of ischemia and hypoxia. The approach relies on methods of multivariate linear regression (MLR) , principle component regression (PCR) and the method of partial least squares (PLS) . These modeling methods are well- established chemometric techniques used in the field of analytical chemistry to estimate the concentration of a material in a mixture from absorption spectra of the mixture. The algorithms and theoretical basis for PLS predictive modeling can be found in Brereton, R.G. Chemometrics : Applications of Mathematics and Statistics to Laboratory Systems. New York: Ellis Horwood, 1990. A basic overview of the PLS regression can be found in Gerald and Kowalski, "Partial Least-Squares Regression: A Tutorial" Analytical Chimica Acta 185 (1986) :1- 17. In the preferred embodiment, the MLR, PCR and the PLS models are trained with LIFA or absorbance spectra as their input and the concentration of both oxygenated and deoxygenated hemoglobin as their outputs. The blood content (i.e. quantity of blood) in the tissue is determined by combining the concentrations of both oxygenated and deoxygenated hemoglobin. The MLR, PCR and the PLS models are trained with LIFA spectra from normal, hypoxic or ischemic rabbit heart and kidney.
Once a model is trained, it can be used to predict the concentrations of oxygenated and deoxygenated hemoglobin if given a LIFA spectrum measured from tissue with unknown oxygenation. The presence and level of hypoxia can be determined by comparing the latter-predicted concentrations values to those known values previously measured from normal tissue. Hypoxic tissue have less oxygenated and more deoxygenated hemoglobin concentrations than normal tissue. Similarly, the presence and level of ischemia can be determined by combining the predicted concentrations to determine the total blood content and then comparing the total blood content to known values of blood content measured in normal tissue. Ischemic tissue will have a lower blood content than normally perfused tissue. The PLS model was found to have the optimal accuracy in detecting the presence and level of ischemia and hypoxia .
Although LIFA or absorbance spectra are the optimal input to the MLR, PCR or PLS models for concentration prediction, it will be appreciated that modulated LIF, or percent transmittance spectra can also be used due to the fact that, even though common LIF represent fluorescence information, the LIF spectra are modulated by wavelength-dependent tissue attenuation. The MAM Classifier
In accordance with the invention, a new mathematical classifier has been developed and applied to categorize spectral data for ischemia or hypoxia detection. The recent multicriteria associative memories (MAM) technique is modified to perform as a data classifier. Similar to existing classifiers, the MAM requires initial training on a set of input-output data pairs. The training process of the MAM classifier involves the calculation of the weights matrix M(η) from the input-output data set using the following learning rule :
M(η) = η R Sτ [η S Sτ + (1-η) I ] _1 (17)
The matrices "S" and "R" holds the input and output training vectors as their columns, respectively. The superscripts τ and "1 indicate matrix transpose and inversion, respectively, and "I" is the identity matrix. The parameter η is initially set to 0.98; however, it can assume any value between 0 and 1 depending on the noise of the system. Following the training stage, the output "r" for an unknown input "s" can be readily calculated from the dot product:
r = M(η) . s (18)
Finally, an appropriate transfer function is used to assign the output "r" into one of several predetermined classification categories . In the present invention, the MAM classifier is initially trained with LIFA (or absorbance) spectra acquired from normal or ischemic tissue as the training inputs. The corresponding normal or ischemic state can be encoded as, for example, "-1" or "1," respectively and used as the training outputs. Therefore, the training LIFA spectra are placed as columns of the input matrix "S" while their corresponding state-coded values are arranged in the same order as elements of the output row vector "R." The number of columns in "S" and elements in "R" are equal to the number of available training sets. A trained MAM matrix can determine whether an unknown LIFA spectrum "s?" has been acquired from normal or ischemic tissue by calculating the dot product r, = M(η) . s, and passing the scalar result "r?" to a hard limit transfer function. The hard limit transfer function then converts any negative or positive values of "r," into "0" or "1" indicating a normal or ischemic classification, respectively. In a similar fashion, the MAM classifier can be applied for the detection of hypoxia and the discrimination between normal, ischemic and hypoxic tissue. It should be apparent that common or intrinsic LIF spectra can replace LIFA spectra as the classifier input. In addition, this input can be an entire spectrum, a re-sampled version of a spectrum or a set of statistical parameters or features characterizing a spectrum. Similarly, actual ischemia or hypoxia levels can be used as the classifier outputs instead of the binary coded output values employed in the above demonstration. In this case a linear transfer function may be used to categorize the output "r" of the MAM classifier.
The MAM technique outperformed the commonly-used artificial neural network (ANN) classifier in accurately classifying LIF/LIFA spectra resulting from normal and ischemic tissue. The superiority of the MAM classifier is most probably due to its insensitivity to spectral noise that might be present in LIF/LIFA spectra measured from biological systems. Although the foregoing MAM classifier is currently applied to discriminate spectral data for the purpose of ischemia or hypoxia detection, it is understood that those skilled in the art may apply it in various ways for different classification purposes . Tissue Characterization
It will also be appreciated that the LIFAS devices and methods can be applied to tissue characterization, i.e., to differentiate between normal and diseased tissue, for tissue diagnostics and malignancy detection. Current LIFS techniques use the intensity spectrum of modulated LIF to identify malignant (cancerous and pre-cancerous ) tissue and classify its type. LIFAS techniques offer a unique tissue characterizing capability not offered by conventional LIFS, based upon measurement of the attenuation spectrum.
A simple demonstration of LIFAS diagnostic capability is shown in FIGS. 17(a)-(d). Although normal kidney and heart tissue are different in nature, their common LIF spectra, shown in FIGS. 17(a) and (b) are almost identical and, hence, are not so usefl for classifiation purposes. However, heart and kidney LIFA spectra, shown in FIG. 17(c) and d are different in terms of both shape and peak attenuation values. Thus, LIFAS techniques offer better tissue identification power than conventional LIFS techniques. Other biomedical applications of the LIFAS methods and devices will include laser removal of decorative tattoos, detection of the in-vivo glucose level, assessment of the degree of burn trauma, detection of atherosclerotic plaque, angioplasty, measurement of acidity or alkalinity, pH measurement, the analysis of biochemical fluids, and the like. For example, measurement of the in vivo skin absorption using LIFAS methods and devices in accordance with the present invention can said in the selection of optimal laser wavelengths for removing tattoos of different colors. Furthermore, since LIFAS techniques can be used to determine absorbance from a hypodermic sample volume, the skin color and the depth of the tattoo dye can be more accurately characterized than in surface reflectance techniques. Similarly, burn injury assessment can be accomplished by using LIFAS techniques to measure the depth of burn by probing for the presence of blood perfusion at varying locations within the tissue. LIFAS techniques can also be used to determine the absorbance or turbidity of a liquid in-situ without the necessity of extracting a sample for use in a spectrometer.
It will be understood by those of ordinary skill in the art that, although the LIFAS system and method is shown in the exemplary method as applied to biological tissue, it is also readily applicable to chemical and industrial material. For example, LIFAS devices and methods can be used to measure the absorbance and/or turbidity of materials and mixtures in medical, food, beverage, detergent, plastic, glass, oil, paint, textile, and semiconductor applications. Furthermore, the concentration of the pure components of the mixture can be determined from the absorbance spectrum using chemometric techniques such as multivariate regression (MLR) , partial least squares (PLS) or artificial neural networks described above. Although the foregoing discloses preferred embodiments of the present invention, it is understood that those skilled in the art may make various changes to the preferred embodiments without departing from the scope of the invention. The invention is defined only by the following claims.

Claims

1. A spectroscopic method of analyzing a sample, comprising: irradiating a sample with radiation to produce return radiation from the sample, wherein the return radiation is modulated by the sample; monitoring a first portion of the modulated return radiation at a first distance from the sample; monitoring a second portion of the modulated return radiation at a second distance from the sample; processing the first and second portions of the modulated return radiation to determine a modulation characteristic of the sample .
2. The method of claim 1, wherein the radiation comprises substantially monochromatic light.
3. The method of claim 1, wherein the radiation comprises laser light.
4. The method of claim 1, wherein the radiation is selected to induce fluorescence in the sample.
5. The method of claim 1, wherein irradiating the sample comprises directing radiation at the sample using a waveguide.
6. The method of claim 5, wherein the waveguide is an optical fiber.
7. The method of claim 5, wherein the waveguide is an optical fiber bundle.
8. The method of claim 1, wherein the return radiation is modulated by attenuation.
9. The method of claims 8 , wherein the return radiation is attenuated by scattering.
10. The method of claim 8, wherein the return radiation is attenuated by absorption.
11. The method of claim 1, wherein the return radiation comprises fluorescence of the sample.
12. The method of claim 1, wherein monitoring of the modulated return radiation comprises: collecting a portion of the modulated return radiation; and determining the intensity of the collected portion of modulated return radiation.
13. The method of claim 12, wherein the first portion of the modulated return radiation is collected with a first waveguide and the second portion of the modulated return radiation is collected with a second waveguide .
14. The method of claim 13, wherein the first waveguide is an optical fiber.
15. The method of claim 13, wherein the first waveguide is an optical fiber bundle.
16. The method of claim 13 , wherein the second waveguide is an optical fiber.
17. The method of claim 13, wherein the second waveguide is an optical fiber bundle.
18. The method of claim 1, wherein irradiating the sample comprises directing radiation to the sample using a first waveguide and wherein the return radiation is monitored using the first waveguide.
19. The method of claim 12, wherein the intensity of the collected portion of the return radiation is determined with a sensor.
20. The method of claim 12, wherein the intensity of the first portion of the modulated return radiation is determined with a sensor.
21. The method of claim 12, wherein the intensity of the second portion of the modulated return radiation is determined with a sensor.
22. The method of claim 12, wherein the intensity of the first portion of the modulated return radiation is determined with a first sensor and the intensity of the second portion of the modulated return radiation is determined with a second sensor.
23. The method of claim 12, wherein the first and second portions of the modulated return radiation are measured consecutively.
24. The method of claim 12, wherein the first and second portions of the modulated return radiation are measured simultaneously.
25. The method of claim 8, wherein the modulation characteristic of the sample is attenuation.
26. The method of claim 8, wherein the modulation characteristic of the sample is absorption.
27. The method of claim 8, wherein the modulation characteristic of the sample is optical rotation.
28. The method of claim 26, wherein the method further includes determining transmittance.
29. The method of claim 11, wherein the method further includes determining the intrinsic fluorescence of the sample .
30. The method of claim 1, wherein the sample is biological material .
31. The method of claim 30, wherein the biological material is living tissue.
32. The method of claim 29, wherein the method further includes determining a physiological property of the biological material using the modulation characteristic.
33. The method of claim 30, wherein the method further includes determining a physiological property of the tissue using the modulation characteristic.
34. The method of claim 33, wherein the physiological property of the tissue is tissue oxygenation.
35. The method of claim 33, wherein the physiological property of the tissue is hypoxia.
36. The method of claim 30, wherein the method further includes determining a pathological property of the biological material using the modulation characteristic.
37. The method of claim 31, wherein the method further includes determining a pathological property of the tissue using the modulation characteristic.
38. The method of claim 37, wherein the pathological property of the tissue is the malignant condition of the tissue.
39. A spectroscopic method for determining the oxygenation of a biological material, comprising: irradiating a sample of a biological material with radiation to produce return radiation from the sample, wherein the return radiation is modulated by attenuation of the sample; monitoring a first portion of the modulated return radiation at a first distance from the sample; monitoring a second portion of the modulated return radiation at a second distance from the sample; processing the first and second portions of the modulated return radiation to determine the attenuation of the sample; determining oxygenation of the sample using the attenuation of the sample.
40. The method of claim 39, wherein the oxygenation of the sample is determined by comparing the attenuation of the sample to the attenuation of a sample having a known level of oxygenation.
41. A spectroscopic method for determining the concentration of hemoglobin in a biological material, comprising: irradiating a sample of a biological material with radiation to produce return radiation from the sample, wherein the return radiation is modulated by attenuation of the sample; monitoring a first portion of the modulate return radiation at a first distance from the sample; monitoring a second portion of the modulated return radiation at a second distance from the sample; determining the concentration of hemoglobin in the sample using the attenuation of the sample.
42. The method of claim 41, wherein the concentration of hemoglobin is determined by comparing the attenuation of the sample to the attenuation of a sample having a known concentration of hemoglobin.
43. A method for determining the oxygenation of a sample, comprising: determining the transmittance of the sample at plurality of wavelengths; determining the wavelength of peak transmittance in the 450- 500 nm range; comparing the wavelength of peak transmittance to the wavelength of peak transmittance of a sample having a known level of oxygenation.
44. A spectroscopic method for the detection of ischemia in a biological sample, comprising: determining the shape of the fluorescence spectrum of a biological sample; identifying a main lobe of the fluorescence spectrum in the wavelength range 350-450 nm; determining the symmetry of the main lobe.
45. The method of claim 44, wherein the symmetry of the main lobe is determined using skewness.
46. The method of claim 45, wherein a small skewness value indicates that the lobe is symmetric.
47. A method for determining a physiological property of a biological sample, comprising: determining the intrinsic fluorescence of the sample; determining a physiological property of the sample using the intrinsic fluorescence.
48. A method for determining a physiological characteristic of a biological material, comprising: irradiating a sample of a biological material with radiation to produce return radiation from the sample, wherein the return radiation is modulated by the sample; monitoring a first portion of the modulated return radiation at a first distance from the sample; monitoring a second portion of the modulated return radiation at a second distance from the sample; processing the first and second portions of the modulated return radiation, using a predictive model, to determine a physiological characteristic of the sample.
49. The method of claim 48, wherein the predictive model is a multivariate linear regression.
50. A method for determining a physiological characteristic of a biological material, comprising: irradiating a sample of a biological material with radiation to produce return radiation from the sample, wherein the return radiation is modulated by the sample; monitoring a first portion of the modulated return radiation at a first distance from the sample; monitoring a second portion of the modulated return radiation at a second distance from the sample; processing the first and second portions of the modulated return radiation to determine a modulation characteristic of the sample processing the modulation characteristic using a predictive model to determine a physiological characteristic of the sample.
51. The method of claim 48, wherein the predictive model is a multicriteria associative memory classifier.
52. Apparatus for analyzing a sample, comprising: a source adapted to emit radiation that is directed at a sample to produce return radiation from the sample, wherein the return radiation is modulated by the sample; a first sensor, displaced by a first distance from the sample, adapted to monitor the return radiation and generate a first signal indicative of the intensity of the return radiation; a second sensor, displaced by a second distance from the sample volume, adapted to monitor the return radiation and generate a second signal indicative of the intensity of return radiation; and
a processor associated with the first sensor and the second sensor and adapted to process the first and second signals to determine a modulation characteristic of the sample.
53. Apparatus for analyzing a sample, comprising: a source adapted to emit radiation that is directed at a sample volume in a sample to produce return light from the sample, such return light including modulated return light resulting from modulation by the sample; a first sensor, displaced by a first distance from the sample volume adapted to monitor the return light and generate a first signal indicative of the intensity of return light; and a second sensor, displaced by a second distance from the sample volume adapted to monitor the return light and generate a second signal indicative of the intensity of return light; a processor associated with the first sensor and the second sensor and adapted to process the first and second signals to determine a modulation characteristic of the sample.
54. Apparatus for determining a modulation characteristic of a biological material, comprising: a source adapted to emit excitation light; a first waveguide disposed a first distance from the sample adapted to transmit the excitation light from the light source to the biological material to cause the biological material to produce return light and adapted to collect a first portion of the return light, such return light including fluorescence of the biological material; a first sensor, associated with the first waveguide, adapted to measure the intensity of the first portion of the return light; a second waveguide disposed at a second distance from the sample adapted to collect a second portion of the return light; a second sensor, associated with the first waveguide, adapted to measure the intensity of the second portion of the return light; a processor adapted to process the first and second signals to determine a modulation characteristic of the biological material .
55. Apparatus for analyzing a sample, comprising: a source adapted to emit radiation that is directed at a sample volume in a sample to produce return light from the sample, such return light including modulated return light resulting from modulation by the sample; a first sensor, displaced by a first distance from the sample volume adapted to monitor the return light and generate a first signal indicative of the intensity of the return light; and a second sensor, displaced by a second distance from the sample volume adapted to monitor the return light and generate a second signal indicative of the intensity of return light; a processor associated with the first sensor and the second sensor and adapted to process the first and second signals to determine a physiological property of the sample.
56. Apparatus for determining a physiological property of biological material, comprising: a source adapted to emit excitation light; a first waveguide disposed a first distance from the sample adapted to transmit the excitation light from the light source to the biological material to cause the biological material to produce return light and adapted to collect a first portion of the return light, such return light including fluorescence of the biological material; a first sensor, associated with the first waveguide, for measuring the intensity of the first portion of the return light; a second waveguide disposed at a second distance from the sample adapted to collect a second portion of the return light; a second sensor, associated with the first waveguide, for measuring the intensity of the second portion of the return light; a processor adapted to process the first and second signals to determine a physiological property of the biological material.
PCT/US1998/011937 1997-07-07 1998-06-09 Method and devices for laser induced fluorescence attenuation spectroscopy (lifas) WO1999002956A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP98926475A EP0995095B1 (en) 1997-07-07 1998-06-09 Method for laser induced fluorescence attenuation spectroscopy (lifas)
AU78306/98A AU752061B2 (en) 1997-07-07 1998-06-09 Method and devices for laser induced fluorescence attenuation spectroscopy (lifas)
JP2000502389A JP2001509589A (en) 1997-07-07 1998-06-09 Method and apparatus for laser-induced fluorescence decay spectroscopy
DE69829664T DE69829664D1 (en) 1997-07-07 1998-06-09 METHOD FOR LASER-INDUCED FLUORESCENT DAMPING SPECTROSCOPY

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/889,017 1997-07-07
US08/889,017 US6124597A (en) 1997-07-07 1997-07-07 Method and devices for laser induced fluorescence attenuation spectroscopy

Publications (2)

Publication Number Publication Date
WO1999002956A2 true WO1999002956A2 (en) 1999-01-21
WO1999002956A3 WO1999002956A3 (en) 1999-04-29

Family

ID=25394356

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/011937 WO1999002956A2 (en) 1997-07-07 1998-06-09 Method and devices for laser induced fluorescence attenuation spectroscopy (lifas)

Country Status (6)

Country Link
US (3) US6124597A (en)
EP (2) EP1562038A3 (en)
JP (1) JP2001509589A (en)
AU (1) AU752061B2 (en)
DE (1) DE69829664D1 (en)
WO (1) WO1999002956A2 (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001052725A1 (en) * 2000-01-21 2001-07-26 Instrumentation Metrics, Inc. Classification and characterization of tissue through features related to adipose tissue
WO2001060246A2 (en) * 2000-02-18 2001-08-23 Argose, Inc. Multivariate analysis of green to ultraviolet spectra of cell and tissue samples
WO2002024048A2 (en) 2000-09-25 2002-03-28 Vital Medical Ltd. Apparatus and method for monitoring tissue vitality parameters
US6377841B1 (en) 2000-03-31 2002-04-23 Vanderbilt University Tumor demarcation using optical spectroscopy
JP2003528678A (en) * 2000-03-31 2003-09-30 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ Method and apparatus for localizing anomalous regions in a turbid medium
WO2004039254A1 (en) * 2002-10-31 2004-05-13 Shanghai Shengbiao Science And Technology Co., Ltd. A laser-induced fluorescence method for precancerous lesion diagnosis and an endoscope precancerous lesion diagnosis apparatus thereof
USRE39672E1 (en) 1997-07-07 2007-06-05 Cedars-Sinai Medical Center Method and devices for laser induced fluorescence attenuation spectroscopy
US7313424B2 (en) 2002-03-20 2007-12-25 Critisense Ltd. Diagnosis of body metabolic emergency state
US7558609B2 (en) 2004-04-06 2009-07-07 National University Corporation Okayama University Cerebral-ischemia supervisory monitor
WO2016166067A1 (en) * 2015-04-17 2016-10-20 Koninklijke Philips N.V. Detection of anisotropic biological tissue
JP2016540558A (en) * 2013-11-14 2016-12-28 ザ・ジョージ・ワシントン・ユニバーシティThe George Washingtonuniversity System and method for determining the depth of damage using fluorescence imaging
CN109270044A (en) * 2018-11-28 2019-01-25 安徽理工大学 A kind of laser induced fluorescence vegetable oil doping strong tea water identification method

Families Citing this family (404)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9702434A (en) 1991-03-07 1998-05-31 Masimo Corp Signal processing apparatus.
US5490505A (en) 1991-03-07 1996-02-13 Masimo Corporation Signal processing apparatus
US5638818A (en) 1991-03-21 1997-06-17 Masimo Corporation Low noise optical probe
EP1905352B1 (en) 1994-10-07 2014-07-16 Masimo Corporation Signal processing method
US8019400B2 (en) 1994-10-07 2011-09-13 Masimo Corporation Signal processing apparatus
US5758644A (en) 1995-06-07 1998-06-02 Masimo Corporation Manual and automatic probe calibration
US6826422B1 (en) 1997-01-13 2004-11-30 Medispectra, Inc. Spectral volume microprobe arrays
US6229856B1 (en) 1997-04-14 2001-05-08 Masimo Corporation Method and apparatus for demodulating signals in a pulse oximetry system
US6002952A (en) 1997-04-14 1999-12-14 Masimo Corporation Signal processing apparatus and method
JP3667947B2 (en) * 1997-08-29 2005-07-06 富士写真フイルム株式会社 Fluorescence image reader
KR20010040418A (en) * 1998-01-26 2001-05-15 자밀라 제트. 허벡 Fluorescence imaging endoscope
US7899518B2 (en) 1998-04-06 2011-03-01 Masimo Laboratories, Inc. Non-invasive tissue glucose level monitoring
US20020091324A1 (en) * 1998-04-06 2002-07-11 Nikiforos Kollias Non-invasive tissue glucose level monitoring
US6728560B2 (en) 1998-04-06 2004-04-27 The General Hospital Corporation Non-invasive tissue glucose level monitoring
ATE521277T1 (en) 1998-06-03 2011-09-15 Masimo Corp STEREO PULSE OXIMETER
USRE41912E1 (en) 1998-10-15 2010-11-02 Masimo Corporation Reusable pulse oximeter probe and disposable bandage apparatus
US7245953B1 (en) 1999-04-12 2007-07-17 Masimo Corporation Reusable pulse oximeter probe and disposable bandage apparatii
US6721585B1 (en) 1998-10-15 2004-04-13 Sensidyne, Inc. Universal modular pulse oximeter probe for use with reusable and disposable patient attachment devices
US6678541B1 (en) * 1998-10-28 2004-01-13 The Governmemt Of The United States Of America Optical fiber probe and methods for measuring optical properties
AU759282B2 (en) 1998-12-23 2003-04-10 Medispectra, Inc. Systems and methods for optical examination of samples
US6463311B1 (en) 1998-12-30 2002-10-08 Masimo Corporation Plethysmograph pulse recognition processor
US6684090B2 (en) 1999-01-07 2004-01-27 Masimo Corporation Pulse oximetry data confidence indicator
US6770028B1 (en) * 1999-01-25 2004-08-03 Masimo Corporation Dual-mode pulse oximeter
US20020140675A1 (en) * 1999-01-25 2002-10-03 Ali Ammar Al System and method for altering a display mode based on a gravity-responsive sensor
DE60024059T2 (en) * 1999-01-26 2006-07-20 Newton Laboratories, Inc., Woburn DEVICE FOR AUTOFLUORESCENT IMAGING FOR AN ENDOSCOPE
US6360114B1 (en) 1999-03-25 2002-03-19 Masimo Corporation Pulse oximeter probe-off detector
DE19922812C2 (en) * 1999-05-19 2001-10-25 Merck Patent Gmbh Measurement of turbidity using reflectometry
US8229549B2 (en) 2004-07-09 2012-07-24 Tyco Healthcare Group Lp Surgical imaging device
US6515273B2 (en) 1999-08-26 2003-02-04 Masimo Corporation System for indicating the expiration of the useful operating life of a pulse oximetry sensor
US6377829B1 (en) 1999-12-09 2002-04-23 Masimo Corporation Resposable pulse oximetry sensor
US6950687B2 (en) 1999-12-09 2005-09-27 Masimo Corporation Isolation and communication element for a resposable pulse oximetry sensor
US6902935B2 (en) * 1999-12-15 2005-06-07 Medispectra, Inc. Methods of monitoring effects of chemical agents on a sample
AU2001237066A1 (en) 2000-02-18 2001-08-27 Argose, Inc. Generation of spatially-averaged excitation-emission map in heterogeneous tissue
AU6501201A (en) * 2000-06-01 2001-12-11 Science Applic Int Corp Systems and methods for monitoring health and delivering drugs transdermally
US6430525B1 (en) 2000-06-05 2002-08-06 Masimo Corporation Variable mode averager
EP2064989B1 (en) 2000-08-18 2012-03-21 Masimo Corporation Dual-mode pulse oximeter
EP1319939A4 (en) * 2000-09-22 2005-11-23 Organo Corp Concentration measurer
US6839661B2 (en) * 2000-12-15 2005-01-04 Medispectra, Inc. System for normalizing spectra
US6704109B2 (en) * 2001-01-23 2004-03-09 Schlumberger Technology Corporation Downhole fluorescence detection apparatus
US7142306B2 (en) * 2001-01-23 2006-11-28 Schlumberger Technology Corporation Optical probes and probe systems for monitoring fluid flow in a well
US7139598B2 (en) * 2002-04-04 2006-11-21 Veralight, Inc. Determination of a measure of a glycation end-product or disease state using tissue fluorescence
US20070276199A1 (en) * 2002-04-04 2007-11-29 Ediger Marwood N Determination of a Measure of a Glycation End-Product or Disease State Using Tissue Fluorescence
WO2002085218A2 (en) 2001-04-20 2002-10-31 Power Medical Interventions, Inc. Bipolar or ultrasonic surgical device
DE60227162D1 (en) * 2001-04-20 2008-07-31 Power Med Interventions Inc ILLUSTRATION DEVICE
US6796710B2 (en) * 2001-06-08 2004-09-28 Ethicon Endo-Surgery, Inc. System and method of measuring and controlling temperature of optical fiber tip in a laser system
US6850787B2 (en) 2001-06-29 2005-02-01 Masimo Laboratories, Inc. Signal component processor
US6697658B2 (en) 2001-07-02 2004-02-24 Masimo Corporation Low power pulse oximeter
WO2003032808A2 (en) 2001-10-15 2003-04-24 University Of Massachusetts Tissue oxygen measurement system
US6750006B2 (en) 2002-01-22 2004-06-15 Microbiosystems, Limited Partnership Method for detecting the presence of microbes and determining their physiological status
US7186990B2 (en) * 2002-01-22 2007-03-06 Microbiosystems, Limited Partnership Method and apparatus for detecting and imaging the presence of biological materials
US7211377B1 (en) 2002-01-22 2007-05-01 Microbiosystems, Limited Partnership Method for detecting the presence of dormant cryptobiotic microorganisms
US7355512B1 (en) 2002-01-24 2008-04-08 Masimo Corporation Parallel alarm processor
CN100443061C (en) 2002-01-30 2008-12-17 能量医学介入公司 Surgical imaging device
US6850788B2 (en) 2002-03-25 2005-02-01 Masimo Corporation Physiological measurement communications adapter
US8131332B2 (en) * 2002-04-04 2012-03-06 Veralight, Inc. Determination of a measure of a glycation end-product or disease state using tissue fluorescence of various sites
US8140147B2 (en) * 2002-04-04 2012-03-20 Veralight, Inc. Determination of a measure of a glycation end-product or disease state using a flexible probe to determine tissue fluorescence of various sites
US20080009689A1 (en) * 2002-04-09 2008-01-10 Benaron David A Difference-weighted somatic spectroscopy
US20070096039A1 (en) * 2002-05-03 2007-05-03 Rakesh Kapoor Evaluation Of Multicomponent Mixtures Using Modulated Light Beams
WO2005075963A1 (en) * 2002-05-03 2005-08-18 Rakesh Kapoor Evaluation of multicomponent mixtures using modulated light beams
US6818903B2 (en) * 2002-07-09 2004-11-16 Medispectra, Inc. Method and apparatus for identifying spectral artifacts
WO2004005895A1 (en) * 2002-07-09 2004-01-15 Medispectra, Inc. Methods and apparatus for characterization of tissue samples
US7103401B2 (en) * 2002-07-10 2006-09-05 Medispectra, Inc. Colonic polyp discrimination by tissue fluorescence and fiberoptic probe
US6768918B2 (en) 2002-07-10 2004-07-27 Medispectra, Inc. Fluorescent fiberoptic probe for tissue health discrimination and method of use thereof
EP1545289B1 (en) 2002-09-30 2010-04-28 Power Medical Interventions, LLC Self-contained sterilizable surgical system
US6970792B1 (en) 2002-12-04 2005-11-29 Masimo Laboratories, Inc. Systems and methods for determining blood oxygen saturation values using complex number encoding
US7919713B2 (en) 2007-04-16 2011-04-05 Masimo Corporation Low noise oximetry cable including conductive cords
US6920345B2 (en) 2003-01-24 2005-07-19 Masimo Corporation Optical sensor including disposable and reusable elements
JP2006522938A (en) * 2003-03-31 2006-10-05 ゾロ テクノロジーズ,インコーポレイティド Method and apparatus for combustion monitoring and control
DE10315541A1 (en) * 2003-04-04 2004-10-28 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Method of determining the degree of freshness of food products is based on the wavelength and radiation intensity of emitted florescent radiation
US7181219B2 (en) * 2003-05-22 2007-02-20 Lucent Technologies Inc. Wireless handover using anchor termination
US7003338B2 (en) 2003-07-08 2006-02-21 Masimo Corporation Method and apparatus for reducing coupling between signals
US7500950B2 (en) 2003-07-25 2009-03-10 Masimo Corporation Multipurpose sensor port
JP2007500529A (en) * 2003-07-31 2007-01-18 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ Method and apparatus with variable numerical aperture for determining the properties of fluid flowing through a biological tube structure
US7254431B2 (en) 2003-08-28 2007-08-07 Masimo Corporation Physiological parameter tracking system
CN100998499B (en) * 2003-10-28 2013-07-24 薇拉莱特公司 Determination of a measure of a glycation end-product or disease state using tissue fluorescence
US7483729B2 (en) 2003-11-05 2009-01-27 Masimo Corporation Pulse oximeter access apparatus and method
US7587236B2 (en) * 2004-01-08 2009-09-08 Lawrence Livermore National Security, Llc Optical spectroscopy for the detection of ischemic tissue injury
US7438683B2 (en) 2004-03-04 2008-10-21 Masimo Corporation Application identification sensor
US7415297B2 (en) 2004-03-08 2008-08-19 Masimo Corporation Physiological parameter system
CA2464029A1 (en) 2004-04-08 2005-10-08 Valery Telfort Non-invasive ventilation monitor
DE102004024494B4 (en) * 2004-05-16 2019-10-17 Dürr Dental SE Medical camera
US7640046B2 (en) * 2004-06-18 2009-12-29 Cardiac Pacemakers, Inc. Methods and apparatuses for localizing myocardial infarction during catheterization
US7343186B2 (en) 2004-07-07 2008-03-11 Masimo Laboratories, Inc. Multi-wavelength physiological monitor
US9341565B2 (en) 2004-07-07 2016-05-17 Masimo Corporation Multiple-wavelength physiological monitor
US7937128B2 (en) 2004-07-09 2011-05-03 Masimo Corporation Cyanotic infant sensor
US8036727B2 (en) 2004-08-11 2011-10-11 Glt Acquisition Corp. Methods for noninvasively measuring analyte levels in a subject
US7254429B2 (en) 2004-08-11 2007-08-07 Glucolight Corporation Method and apparatus for monitoring glucose levels in a biological tissue
CN101137323A (en) * 2004-12-09 2008-03-05 弹性医疗系统有限责任公司 Apparatus and method for continuous real-time trace biomolecular sampling, analysis and delivery
US7491943B2 (en) * 2005-01-13 2009-02-17 Whitehead Institute For Biomedical Research Method and apparatus for UV imaging
US20060189871A1 (en) 2005-02-18 2006-08-24 Ammar Al-Ali Portable patient monitor
US7596398B2 (en) 2005-03-01 2009-09-29 Masimo Laboratories, Inc. Multiple wavelength sensor attachment
EP1874178A4 (en) 2005-04-13 2009-12-09 Glucolight Corp Method for data reduction and calibration of an oct-based blood glucose monitor
CA2610856A1 (en) * 2005-06-13 2006-12-28 Stratagene California System and method for fluorescence excitation and detection having distinct optical paths
DE102005045906B4 (en) * 2005-09-26 2007-11-29 Siemens Ag Device for receiving a tissue containing a fluorescent dye
US7962188B2 (en) 2005-10-14 2011-06-14 Masimo Corporation Robust alarm system
US7530942B1 (en) 2005-10-18 2009-05-12 Masimo Corporation Remote sensing infant warmer
US8233955B2 (en) 2005-11-29 2012-07-31 Cercacor Laboratories, Inc. Optical sensor including disposable and reusable elements
EP1962671A2 (en) * 2005-12-03 2008-09-03 Masimo Corporation Physiological alarm notification system
US7847941B2 (en) * 2005-12-07 2010-12-07 Los Alamos National Security, Llc Fiber optical assembly for fluorescence spectrometry
US8333874B2 (en) * 2005-12-09 2012-12-18 Flexible Medical Systems, Llc Flexible apparatus and method for monitoring and delivery
US7990382B2 (en) 2006-01-03 2011-08-02 Masimo Corporation Virtual display
US8182443B1 (en) 2006-01-17 2012-05-22 Masimo Corporation Drug administration controller
US20090306533A1 (en) * 2006-01-26 2009-12-10 Rousche Patrick J Stroke Inducing and Monitoring System and Method for Using the Same
GB0604231D0 (en) * 2006-03-02 2006-04-12 Ucl Biomedica Plc Cancer detection system
US20070244377A1 (en) * 2006-03-14 2007-10-18 Cozad Jenny L Pulse oximeter sleeve
US8219172B2 (en) 2006-03-17 2012-07-10 Glt Acquisition Corp. System and method for creating a stable optical interface
US7846390B2 (en) * 2006-03-30 2010-12-07 King Fahd University Of Petroleum And Minerals Apparatus and method for measuring concentrations of fuel mixtures using depth-resolved laser-induced fluorescence
US9176141B2 (en) 2006-05-15 2015-11-03 Cercacor Laboratories, Inc. Physiological monitor calibration system
US7941199B2 (en) 2006-05-15 2011-05-10 Masimo Laboratories, Inc. Sepsis monitor
US8998809B2 (en) 2006-05-15 2015-04-07 Cercacor Laboratories, Inc. Systems and methods for calibrating minimally invasive and non-invasive physiological sensor devices
US8028701B2 (en) 2006-05-31 2011-10-04 Masimo Corporation Respiratory monitoring
US10188348B2 (en) 2006-06-05 2019-01-29 Masimo Corporation Parameter upgrade system
US20080039735A1 (en) * 2006-06-06 2008-02-14 Hickerson Barry L Respiratory monitor display
US20080064965A1 (en) * 2006-09-08 2008-03-13 Jay Gregory D Devices and methods for measuring pulsus paradoxus
USD614305S1 (en) 2008-02-29 2010-04-20 Masimo Corporation Connector assembly
US8315683B2 (en) 2006-09-20 2012-11-20 Masimo Corporation Duo connector patient cable
US8457707B2 (en) 2006-09-20 2013-06-04 Masimo Corporation Congenital heart disease monitor
USD609193S1 (en) 2007-10-12 2010-02-02 Masimo Corporation Connector assembly
US20080103375A1 (en) * 2006-09-22 2008-05-01 Kiani Massi E Patient monitor user interface
US9161696B2 (en) 2006-09-22 2015-10-20 Masimo Corporation Modular patient monitor
US8840549B2 (en) 2006-09-22 2014-09-23 Masimo Corporation Modular patient monitor
US9192329B2 (en) 2006-10-12 2015-11-24 Masimo Corporation Variable mode pulse indicator
US20080094228A1 (en) * 2006-10-12 2008-04-24 Welch James P Patient monitor using radio frequency identification tags
US8265723B1 (en) 2006-10-12 2012-09-11 Cercacor Laboratories, Inc. Oximeter probe off indicator defining probe off space
US9861305B1 (en) 2006-10-12 2018-01-09 Masimo Corporation Method and apparatus for calibration to reduce coupling between signals in a measurement system
US7880626B2 (en) 2006-10-12 2011-02-01 Masimo Corporation System and method for monitoring the life of a physiological sensor
WO2008045538A2 (en) 2006-10-12 2008-04-17 Masimo Corporation Perfusion index smoother
US8255026B1 (en) 2006-10-12 2012-08-28 Masimo Corporation, Inc. Patient monitor capable of monitoring the quality of attached probes and accessories
DE102006048317A1 (en) * 2006-10-12 2008-04-17 Robert Bosch Gmbh Optical fiber sensor for optical measuring device i.e. interferometric measuring device, has optical fiber modularly provided with mechanically stabilizing coating in area of fiber end piece and/or in area of mechanical receiver
US8600467B2 (en) 2006-11-29 2013-12-03 Cercacor Laboratories, Inc. Optical sensor including disposable and reusable elements
US8414499B2 (en) 2006-12-09 2013-04-09 Masimo Corporation Plethysmograph variability processor
US8852094B2 (en) 2006-12-22 2014-10-07 Masimo Corporation Physiological parameter system
US7791155B2 (en) 2006-12-22 2010-09-07 Masimo Laboratories, Inc. Detector shield
US8652060B2 (en) 2007-01-20 2014-02-18 Masimo Corporation Perfusion trend indicator
EP2118642B1 (en) * 2007-02-12 2015-09-02 Koninklijke Philips N.V. Wiregrid monitor device
US8101426B2 (en) * 2007-03-02 2012-01-24 Icyt Mission Technology, Inc. System and method for the measurement of multiple fluorescence emissions in a flow cytometry system
EP2476369B1 (en) 2007-03-27 2014-10-01 Masimo Laboratories, Inc. Multiple wavelength optical sensor
US8374665B2 (en) 2007-04-21 2013-02-12 Cercacor Laboratories, Inc. Tissue profile wellness monitor
US8764671B2 (en) 2007-06-28 2014-07-01 Masimo Corporation Disposable active pulse sensor
AU2008311221B2 (en) 2007-07-13 2014-08-21 University Of Massachusetts Physical performance monitoring and monitors
US8048040B2 (en) 2007-09-13 2011-11-01 Masimo Corporation Fluid titration system
EP2227843B1 (en) 2007-10-12 2019-03-06 Masimo Corporation Connector assembly
US8310336B2 (en) 2008-10-10 2012-11-13 Masimo Corporation Systems and methods for storing, analyzing, retrieving and displaying streaming medical data
US8274360B2 (en) 2007-10-12 2012-09-25 Masimo Corporation Systems and methods for storing, analyzing, and retrieving medical data
US8355766B2 (en) 2007-10-12 2013-01-15 Masimo Corporation Ceramic emitter substrate
US8553337B2 (en) * 2007-11-12 2013-10-08 Cornell University Multi-path, multi-magnification, non-confocal fluorescence emission endoscopy apparatus and methods
WO2009064753A1 (en) * 2007-11-12 2009-05-22 Cornell University Non-imaging, weakly focused fluorescence emission apparatus and methods
US9717896B2 (en) 2007-12-18 2017-08-01 Gearbox, Llc Treatment indications informed by a priori implant information
US9672471B2 (en) 2007-12-18 2017-06-06 Gearbox Llc Systems, devices, and methods for detecting occlusions in a biological subject including spectral learning
US20090287120A1 (en) 2007-12-18 2009-11-19 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Circulatory monitoring systems and methods
US8636670B2 (en) 2008-05-13 2014-01-28 The Invention Science Fund I, Llc Circulatory monitoring systems and methods
US8280484B2 (en) 2007-12-18 2012-10-02 The Invention Science Fund I, Llc System, devices, and methods for detecting occlusions in a biological subject
DE202008009859U1 (en) * 2007-12-21 2009-03-05 Berthold Technologies Gmbh & Co. Kg Device for the optional measurement of in particular luminescence and / or fluorescence radiation
WO2009111542A2 (en) 2008-03-04 2009-09-11 Glucolight Corporation Methods and systems for analyte level estimation in optical coherence tomography
EP2278911A1 (en) 2008-05-02 2011-02-02 Masimo Corporation Monitor configuration system
JP2011519684A (en) 2008-05-05 2011-07-14 マシモ コーポレイション Pulse oximeter system with electrical disconnect circuit
US9042967B2 (en) 2008-05-20 2015-05-26 University Health Network Device and method for wound imaging and monitoring
USD621516S1 (en) 2008-08-25 2010-08-10 Masimo Laboratories, Inc. Patient monitoring sensor
EP2326239B1 (en) 2008-07-03 2017-06-21 Masimo Laboratories, Inc. Protrusion for improving spectroscopic measurement of blood constituents
US8512975B2 (en) * 2008-07-24 2013-08-20 Biomerieux, Inc. Method for detection and characterization of a microorganism in a sample using time dependent spectroscopic measurements
US8203438B2 (en) 2008-07-29 2012-06-19 Masimo Corporation Alarm suspend system
US8203704B2 (en) 2008-08-04 2012-06-19 Cercacor Laboratories, Inc. Multi-stream sensor for noninvasive measurement of blood constituents
WO2010031070A2 (en) 2008-09-15 2010-03-18 Masimo Corporation Patient monitor including multi-parameter graphical display
SE532941C2 (en) 2008-09-15 2010-05-18 Phasein Ab Gas sampling line for breathing gases
US8401602B2 (en) 2008-10-13 2013-03-19 Masimo Corporation Secondary-emitter sensor position indicator
US8346330B2 (en) 2008-10-13 2013-01-01 Masimo Corporation Reflection-detector sensor position indicator
US10167494B2 (en) * 2008-10-31 2019-01-01 Biomerieux, Inc. Method for detection, characterization and/or identification of microorganisms in a sealed container
US8771204B2 (en) 2008-12-30 2014-07-08 Masimo Corporation Acoustic sensor assembly
AU2010203674B2 (en) 2009-01-09 2014-09-25 Onpoint Technologies, Llc Method and apparatus for monitoring combustion properties in an interior of a boiler
US8588880B2 (en) 2009-02-16 2013-11-19 Masimo Corporation Ear sensor
US9323894B2 (en) 2011-08-19 2016-04-26 Masimo Corporation Health care sanitation monitoring system
US10007758B2 (en) 2009-03-04 2018-06-26 Masimo Corporation Medical monitoring system
EP3605550A1 (en) 2009-03-04 2020-02-05 Masimo Corporation Medical monitoring system
US10032002B2 (en) 2009-03-04 2018-07-24 Masimo Corporation Medical monitoring system
US8388353B2 (en) 2009-03-11 2013-03-05 Cercacor Laboratories, Inc. Magnetic connector
US20100234718A1 (en) * 2009-03-12 2010-09-16 Anand Sampath Open architecture medical communication system
US8897847B2 (en) 2009-03-23 2014-11-25 Masimo Corporation Digit gauge for noninvasive optical sensor
AU2010229864A1 (en) * 2009-03-25 2011-10-27 Los Alamos National Security, Llc Rapid antemortem detection of infectious agents
CN102362179A (en) 2009-03-25 2012-02-22 洛斯阿拉莫斯国家安全有限责任公司 Fiber optical assembly for fluorescence spectrometry
US8989831B2 (en) 2009-05-19 2015-03-24 Masimo Corporation Disposable components for reusable physiological sensor
US8571619B2 (en) 2009-05-20 2013-10-29 Masimo Corporation Hemoglobin display and patient treatment
US8418524B2 (en) 2009-06-12 2013-04-16 Masimo Corporation Non-invasive sensor calibration device
US8670811B2 (en) 2009-06-30 2014-03-11 Masimo Corporation Pulse oximetry system for adjusting medical ventilation
US20110040197A1 (en) * 2009-07-20 2011-02-17 Masimo Corporation Wireless patient monitoring system
US20110208015A1 (en) * 2009-07-20 2011-08-25 Masimo Corporation Wireless patient monitoring system
US8471713B2 (en) 2009-07-24 2013-06-25 Cercacor Laboratories, Inc. Interference detector for patient monitor
US20110028806A1 (en) * 2009-07-29 2011-02-03 Sean Merritt Reflectance calibration of fluorescence-based glucose measurements
US8473020B2 (en) 2009-07-29 2013-06-25 Cercacor Laboratories, Inc. Non-invasive physiological sensor cover
US20110028809A1 (en) * 2009-07-29 2011-02-03 Masimo Corporation Patient monitor ambient display device
US20110087081A1 (en) * 2009-08-03 2011-04-14 Kiani Massi Joe E Personalized physiological monitor
US8688183B2 (en) 2009-09-03 2014-04-01 Ceracor Laboratories, Inc. Emitter driver for noninvasive patient monitor
JP2011053135A (en) * 2009-09-03 2011-03-17 Japan Aerospace Exploration Agency Device and method for multi-wavelength fluorescence imaging for evaluation of biological metabolic function
US20110172498A1 (en) 2009-09-14 2011-07-14 Olsen Gregory A Spot check monitor credit system
US9579039B2 (en) 2011-01-10 2017-02-28 Masimo Corporation Non-invasive intravascular volume index monitor
US20110137297A1 (en) 2009-09-17 2011-06-09 Kiani Massi Joe E Pharmacological management system
DE112010003689T5 (en) 2009-09-17 2013-01-17 Marcelo Lamego Improved analyte monitoring using one or more accelerometers
US8571618B1 (en) 2009-09-28 2013-10-29 Cercacor Laboratories, Inc. Adaptive calibration system for spectrophotometric measurements
US8401608B2 (en) * 2009-09-30 2013-03-19 Covidien Lp Method of analyzing photon density waves in a medical monitor
US20110082711A1 (en) 2009-10-06 2011-04-07 Masimo Laboratories, Inc. Personal digital assistant or organizer for monitoring glucose levels
US8715206B2 (en) 2009-10-15 2014-05-06 Masimo Corporation Acoustic patient sensor
US8821415B2 (en) 2009-10-15 2014-09-02 Masimo Corporation Physiological acoustic monitoring system
US8523781B2 (en) 2009-10-15 2013-09-03 Masimo Corporation Bidirectional physiological information display
US9066680B1 (en) 2009-10-15 2015-06-30 Masimo Corporation System for determining confidence in respiratory rate measurements
WO2011047216A2 (en) 2009-10-15 2011-04-21 Masimo Corporation Physiological acoustic monitoring system
WO2011047211A1 (en) 2009-10-15 2011-04-21 Masimo Corporation Pulse oximetry system with low noise cable hub
US9848800B1 (en) 2009-10-16 2017-12-26 Masimo Corporation Respiratory pause detector
CA2781040A1 (en) * 2009-11-17 2011-05-26 Veralight, Inc. Method and apparatus to detect coronary artery calcification or disease
US9839381B1 (en) 2009-11-24 2017-12-12 Cercacor Laboratories, Inc. Physiological measurement system with automatic wavelength adjustment
DE112010004682T5 (en) 2009-12-04 2013-03-28 Masimo Corporation Calibration for multi-level physiological monitors
US9153112B1 (en) 2009-12-21 2015-10-06 Masimo Corporation Modular patient monitor
GB2490817A (en) 2010-01-19 2012-11-14 Masimo Corp Wellness analysis system
GB2490832B (en) 2010-03-01 2016-09-21 Masimo Corp Adaptive alarm system
EP2544591B1 (en) 2010-03-08 2021-07-21 Masimo Corporation Reprocessing of a physiological sensor
JP2011185842A (en) 2010-03-10 2011-09-22 Fujifilm Corp Method and device for analyzing low oxygen region of biosample by time resolving measurement of light induced self-fluorescence
US9307928B1 (en) 2010-03-30 2016-04-12 Masimo Corporation Plethysmographic respiration processor
US8655807B2 (en) 2010-04-05 2014-02-18 Applied Research Associates, Inc. Methods for forming recognition algorithms for laser-induced breakdown spectroscopy
US9138180B1 (en) 2010-05-03 2015-09-22 Masimo Corporation Sensor adapter cable
US8712494B1 (en) 2010-05-03 2014-04-29 Masimo Corporation Reflective non-invasive sensor
US8666468B1 (en) 2010-05-06 2014-03-04 Masimo Corporation Patient monitor for determining microcirculation state
US9326712B1 (en) 2010-06-02 2016-05-03 Masimo Corporation Opticoustic sensor
US8740792B1 (en) 2010-07-12 2014-06-03 Masimo Corporation Patient monitor capable of accounting for environmental conditions
US9408542B1 (en) 2010-07-22 2016-08-09 Masimo Corporation Non-invasive blood pressure measurement system
WO2012027613A1 (en) 2010-08-26 2012-03-01 Masimo Corporation Blood pressure measurement system
JP5710767B2 (en) 2010-09-28 2015-04-30 マシモ コーポレイション Depth of consciousness monitor including oximeter
US9775545B2 (en) 2010-09-28 2017-10-03 Masimo Corporation Magnetic electrical connector for patient monitors
US9995681B2 (en) * 2010-09-28 2018-06-12 Authentix, Inc. Determining the quantity of a taggant in a liquid sample
US9211095B1 (en) 2010-10-13 2015-12-15 Masimo Corporation Physiological measurement logic engine
US8723677B1 (en) 2010-10-20 2014-05-13 Masimo Corporation Patient safety system with automatically adjusting bed
EP2620093A1 (en) * 2010-10-29 2013-07-31 Olympus Corporation Optical measurement device and probe
US20120226117A1 (en) 2010-12-01 2012-09-06 Lamego Marcelo M Handheld processing device including medical applications for minimally and non invasive glucose measurements
US9877673B2 (en) 2010-12-10 2018-01-30 Clinitech, Llc Transdermal sampling and analysis device
US9451913B2 (en) 2010-12-10 2016-09-27 Touchtek Labs, Llc Transdermal sampling and analysis device
WO2012109671A1 (en) 2011-02-13 2012-08-16 Masimo Corporation Medical characterization system
US9066666B2 (en) 2011-02-25 2015-06-30 Cercacor Laboratories, Inc. Patient monitor for monitoring microcirculation
US8830449B1 (en) 2011-04-18 2014-09-09 Cercacor Laboratories, Inc. Blood analysis system
US9095316B2 (en) 2011-04-20 2015-08-04 Masimo Corporation System for generating alarms based on alarm patterns
US9622692B2 (en) 2011-05-16 2017-04-18 Masimo Corporation Personal health device
US9986919B2 (en) 2011-06-21 2018-06-05 Masimo Corporation Patient monitoring system
US9532722B2 (en) 2011-06-21 2017-01-03 Masimo Corporation Patient monitoring system
US9245668B1 (en) 2011-06-29 2016-01-26 Cercacor Laboratories, Inc. Low noise cable providing communication between electronic sensor components and patient monitor
US11439329B2 (en) 2011-07-13 2022-09-13 Masimo Corporation Multiple measurement mode in a physiological sensor
US9192351B1 (en) 2011-07-22 2015-11-24 Masimo Corporation Acoustic respiratory monitoring sensor with probe-off detection
US8755872B1 (en) 2011-07-28 2014-06-17 Masimo Corporation Patient monitoring system for indicating an abnormal condition
US9782077B2 (en) 2011-08-17 2017-10-10 Masimo Corporation Modulated physiological sensor
KR20140102643A (en) 2011-09-22 2014-08-22 더 조지 워싱턴 유니버시티 Systems and methods for visualizing ablated tissue
EP2757933B1 (en) 2011-09-22 2019-02-06 The George Washington University Systems for visualizing ablated tissue
EP2765909B1 (en) 2011-10-13 2019-06-26 Masimo Corporation Physiological acoustic monitoring system
EP3584799B1 (en) 2011-10-13 2022-11-09 Masimo Corporation Medical monitoring hub
US9943269B2 (en) 2011-10-13 2018-04-17 Masimo Corporation System for displaying medical monitoring data
US9808188B1 (en) 2011-10-13 2017-11-07 Masimo Corporation Robust fractional saturation determination
US9778079B1 (en) 2011-10-27 2017-10-03 Masimo Corporation Physiological monitor gauge panel
JP5970785B2 (en) * 2011-11-16 2016-08-17 ソニー株式会社 Biological measuring device, biological measuring method, program, and recording medium
US9968284B2 (en) 2011-12-02 2018-05-15 Clinitech, Llc Anti-interferent barrier layers for non-invasive transdermal sampling and analysis device
US9445759B1 (en) 2011-12-22 2016-09-20 Cercacor Laboratories, Inc. Blood glucose calibration system
US9392945B2 (en) 2012-01-04 2016-07-19 Masimo Corporation Automated CCHD screening and detection
US11172890B2 (en) 2012-01-04 2021-11-16 Masimo Corporation Automated condition screening and detection
US10149616B2 (en) 2012-02-09 2018-12-11 Masimo Corporation Wireless patient monitoring device
US9480435B2 (en) 2012-02-09 2016-11-01 Masimo Corporation Configurable patient monitoring system
US10307111B2 (en) 2012-02-09 2019-06-04 Masimo Corporation Patient position detection system
US9195385B2 (en) 2012-03-25 2015-11-24 Masimo Corporation Physiological monitor touchscreen interface
US9131881B2 (en) 2012-04-17 2015-09-15 Masimo Corporation Hypersaturation index
ES2644601T3 (en) 2012-04-19 2017-11-29 Zolo Technologies, Inc. Retroreflectors in the oven with the tunable diode laser absorption absorption spectrometer
RU2511262C2 (en) * 2012-05-29 2014-04-10 Общество с ограниченной ответственностью "Научно-производственный центр медицинских и промышленных биотехнологий Спектролюкс" Method for monitoring of treatment of disease involving fluorescence diagnostics of disease, and device for implementing it
US10542903B2 (en) 2012-06-07 2020-01-28 Masimo Corporation Depth of consciousness monitor
US20160112684A1 (en) * 2013-05-23 2016-04-21 Medibotics Llc Spectroscopic Finger Ring for Compositional Analysis of Food or Other Environmental Objects
US9697928B2 (en) 2012-08-01 2017-07-04 Masimo Corporation Automated assembly sensor cable
US10827961B1 (en) 2012-08-29 2020-11-10 Masimo Corporation Physiological measurement calibration
US9955937B2 (en) 2012-09-20 2018-05-01 Masimo Corporation Acoustic patient sensor coupler
US9877650B2 (en) 2012-09-20 2018-01-30 Masimo Corporation Physiological monitor with mobile computing device connectivity
US9749232B2 (en) 2012-09-20 2017-08-29 Masimo Corporation Intelligent medical network edge router
US9717458B2 (en) 2012-10-20 2017-08-01 Masimo Corporation Magnetic-flap optical sensor
US9560996B2 (en) 2012-10-30 2017-02-07 Masimo Corporation Universal medical system
US9787568B2 (en) 2012-11-05 2017-10-10 Cercacor Laboratories, Inc. Physiological test credit method
US9750461B1 (en) 2013-01-02 2017-09-05 Masimo Corporation Acoustic respiratory monitoring sensor with probe-off detection
US9724025B1 (en) 2013-01-16 2017-08-08 Masimo Corporation Active-pulse blood analysis system
US9750442B2 (en) 2013-03-09 2017-09-05 Masimo Corporation Physiological status monitor
US10441181B1 (en) 2013-03-13 2019-10-15 Masimo Corporation Acoustic pulse and respiration monitoring system
US9965946B2 (en) 2013-03-13 2018-05-08 Masimo Corporation Systems and methods for monitoring a patient health network
US9474474B2 (en) 2013-03-14 2016-10-25 Masimo Corporation Patient monitor as a minimally invasive glucometer
US9936917B2 (en) 2013-03-14 2018-04-10 Masimo Laboratories, Inc. Patient monitor placement indicator
US9986952B2 (en) 2013-03-14 2018-06-05 Masimo Corporation Heart sound simulator
US10004434B1 (en) 2013-03-15 2018-06-26 Georgetown University Microfluidic systems for electrochemical transdermal analyte sensing using a capillary-located electrode
US10456038B2 (en) 2013-03-15 2019-10-29 Cercacor Laboratories, Inc. Cloud-based physiological monitoring system
WO2014168734A1 (en) * 2013-03-15 2014-10-16 Cedars-Sinai Medical Center Time-resolved laser-induced fluorescence spectroscopy systems and uses thereof
RU2539817C1 (en) * 2013-07-16 2015-01-27 Федеральное государственное бюджетное учреждение "Федеральный Центр сердца, крови и Эндокринологии имени В.А. Алмазова" Министерства здравоохранения Российской Федерации Apparatus for fluorescent spectroscopy of biological tissue
US9891079B2 (en) 2013-07-17 2018-02-13 Masimo Corporation Pulser with double-bearing position encoder for non-invasive physiological monitoring
US10555678B2 (en) 2013-08-05 2020-02-11 Masimo Corporation Blood pressure monitor with valve-chamber assembly
WO2015038683A2 (en) 2013-09-12 2015-03-19 Cercacor Laboratories, Inc. Medical device management system
WO2015054161A2 (en) 2013-10-07 2015-04-16 Masimo Corporation Regional oximetry sensor
US11147518B1 (en) 2013-10-07 2021-10-19 Masimo Corporation Regional oximetry signal processor
US10828007B1 (en) 2013-10-11 2020-11-10 Masimo Corporation Acoustic sensor with attachment portion
US10832818B2 (en) 2013-10-11 2020-11-10 Masimo Corporation Alarm notification system
JP2017500550A (en) 2013-11-20 2017-01-05 ザ・ジョージ・ワシントン・ユニバーシティThe George Washingtonuniversity System and method for hyperspectral analysis of cardiac tissue
US10279247B2 (en) 2013-12-13 2019-05-07 Masimo Corporation Avatar-incentive healthcare therapy
US11259745B2 (en) 2014-01-28 2022-03-01 Masimo Corporation Autonomous drug delivery system
US10086138B1 (en) 2014-01-28 2018-10-02 Masimo Corporation Autonomous drug delivery system
US10532174B2 (en) 2014-02-21 2020-01-14 Masimo Corporation Assistive capnography device
RU2551634C1 (en) * 2014-04-28 2015-05-27 Закрытое акционерное общество "Полупроводниковые приборы" Device for fluorescent diagnostics of malignant neoplasms
US9924897B1 (en) 2014-06-12 2018-03-27 Masimo Corporation Heated reprocessing of physiological sensors
US10123729B2 (en) 2014-06-13 2018-11-13 Nanthealth, Inc. Alarm fatigue management systems and methods
US10231670B2 (en) 2014-06-19 2019-03-19 Masimo Corporation Proximity sensor in pulse oximeter
CN115989999A (en) 2014-07-24 2023-04-21 大学健康网络 Collection and analysis of data for diagnostic purposes
US10111591B2 (en) 2014-08-26 2018-10-30 Nanthealth, Inc. Real-time monitoring systems and methods in a healthcare environment
WO2016036985A1 (en) 2014-09-04 2016-03-10 Masimo Corportion Total hemoglobin index system
US10383520B2 (en) 2014-09-18 2019-08-20 Masimo Semiconductor, Inc. Enhanced visible near-infrared photodiode and non-invasive physiological sensor
WO2016057553A1 (en) 2014-10-07 2016-04-14 Masimo Corporation Modular physiological sensors
WO2016073476A1 (en) 2014-11-03 2016-05-12 The George Washington University Systems and methods for lesion assessment
CN107427213B (en) 2014-11-03 2021-04-16 460医学股份有限公司 System and method for evaluation of contact quality
CN104483299A (en) * 2014-12-10 2015-04-01 安徽理工大学 Method for identifying water hazard water source of mining area
WO2016118922A1 (en) 2015-01-23 2016-07-28 Masimo Sweden Ab Nasal/oral cannula system and manufacturing
US10568553B2 (en) 2015-02-06 2020-02-25 Masimo Corporation Soft boot pulse oximetry sensor
USD755392S1 (en) 2015-02-06 2016-05-03 Masimo Corporation Pulse oximetry sensor
EP3254339A1 (en) 2015-02-06 2017-12-13 Masimo Corporation Connector assembly with pogo pins for use with medical sensors
CA2974830C (en) 2015-02-06 2023-06-27 Masimo Corporation Fold flex circuit for lnop
US10524738B2 (en) 2015-05-04 2020-01-07 Cercacor Laboratories, Inc. Noninvasive sensor system with visual infographic display
WO2016191307A1 (en) 2015-05-22 2016-12-01 Cercacor Laboratories, Inc. Non-invasive optical physiological differential pathlength sensor
US10448871B2 (en) 2015-07-02 2019-10-22 Masimo Corporation Advanced pulse oximetry sensor
US10779904B2 (en) 2015-07-19 2020-09-22 460Medical, Inc. Systems and methods for lesion formation and assessment
WO2017023931A1 (en) 2015-08-03 2017-02-09 Georgetown University Apparatus and method for delivery of antimicrobial during a transdermal sampling and delivery process
US11656180B2 (en) 2015-08-03 2023-05-23 Ysi, Inc. Multi excitation-multi emission fluorometer for multiparameter water quality monitoring
CN108351300A (en) * 2015-08-03 2018-07-31 Ysi公司 More excitations-multi-emitting fluorimeter for multi-parameter water quality monitoring
JP6855443B2 (en) 2015-08-11 2021-04-07 マシモ・コーポレイション Medical monitoring analysis and regeneration including identification marks that respond to light reduced by body tissue
US10226187B2 (en) 2015-08-31 2019-03-12 Masimo Corporation Patient-worn wireless physiological sensor
US11504066B1 (en) 2015-09-04 2022-11-22 Cercacor Laboratories, Inc. Low-noise sensor system
US11679579B2 (en) 2015-12-17 2023-06-20 Masimo Corporation Varnish-coated release liner
US10799129B2 (en) * 2016-01-07 2020-10-13 Panasonic Intellectual Property Management Co., Ltd. Biological information measuring device including light source, light detector, and control circuit
US10537285B2 (en) 2016-03-04 2020-01-21 Masimo Corporation Nose sensor
US10993662B2 (en) 2016-03-04 2021-05-04 Masimo Corporation Nose sensor
US10656089B2 (en) 2016-04-01 2020-05-19 Black Light Surgical, Inc. Systems, devices, and methods for time-resolved fluorescent spectroscopy
US11191484B2 (en) 2016-04-29 2021-12-07 Masimo Corporation Optical sensor tape
WO2018009612A1 (en) 2016-07-06 2018-01-11 Patient Doctor Technologies, Inc. Secure and zero knowledge data sharing for cloud applications
US10617302B2 (en) 2016-07-07 2020-04-14 Masimo Corporation Wearable pulse oximeter and respiration monitor
JP7197473B2 (en) 2016-10-13 2022-12-27 マシモ・コーポレイション System and method for patient fall detection
US11504058B1 (en) 2016-12-02 2022-11-22 Masimo Corporation Multi-site noninvasive measurement of a physiological parameter
WO2018119239A1 (en) 2016-12-22 2018-06-28 Cercacor Laboratories, Inc Methods and devices for detecting intensity of light with translucent detector
US10721785B2 (en) 2017-01-18 2020-07-21 Masimo Corporation Patient-worn wireless physiological sensor with pairing functionality
WO2018156804A1 (en) 2017-02-24 2018-08-30 Masimo Corporation System for displaying medical monitoring data
US10388120B2 (en) 2017-02-24 2019-08-20 Masimo Corporation Localized projection of audible noises in medical settings
WO2018156648A1 (en) 2017-02-24 2018-08-30 Masimo Corporation Managing dynamic licenses for physiological parameters in a patient monitoring environment
US11086609B2 (en) 2017-02-24 2021-08-10 Masimo Corporation Medical monitoring hub
US10327713B2 (en) 2017-02-24 2019-06-25 Masimo Corporation Modular multi-parameter patient monitoring device
WO2018156809A1 (en) 2017-02-24 2018-08-30 Masimo Corporation Augmented reality system for displaying patient data
EP3592231A1 (en) 2017-03-10 2020-01-15 Masimo Corporation Pneumonia screener
WO2018194992A1 (en) 2017-04-18 2018-10-25 Masimo Corporation Nose sensor
US10918281B2 (en) 2017-04-26 2021-02-16 Masimo Corporation Medical monitoring device having multiple configurations
JP7278220B2 (en) 2017-04-28 2023-05-19 マシモ・コーポレイション Spot check measurement system
USD835285S1 (en) 2017-04-28 2018-12-04 Masimo Corporation Medical monitoring device
USD835284S1 (en) 2017-04-28 2018-12-04 Masimo Corporation Medical monitoring device
USD835283S1 (en) 2017-04-28 2018-12-04 Masimo Corporation Medical monitoring device
USD835282S1 (en) 2017-04-28 2018-12-04 Masimo Corporation Medical monitoring device
EP3622529A1 (en) 2017-05-08 2020-03-18 Masimo Corporation System for pairing a medical system to a network controller by use of a dongle
WO2019014629A1 (en) 2017-07-13 2019-01-17 Cercacor Laboratories, Inc. Medical monitoring device for harmonizing physiological measurements
USD906970S1 (en) 2017-08-15 2021-01-05 Masimo Corporation Connector
USD890708S1 (en) 2017-08-15 2020-07-21 Masimo Corporation Connector
US10637181B2 (en) 2017-08-15 2020-04-28 Masimo Corporation Water resistant connector for noninvasive patient monitor
WO2019079643A1 (en) 2017-10-19 2019-04-25 Masimo Corporation Display arrangement for medical monitoring system
JP2019078715A (en) * 2017-10-27 2019-05-23 セイコーエプソン株式会社 Spectrometry device and method for spectrometry
WO2019089655A1 (en) 2017-10-31 2019-05-09 Masimo Corporation System for displaying oxygen state indications
USD925597S1 (en) 2017-10-31 2021-07-20 Masimo Corporation Display screen or portion thereof with graphical user interface
US11766198B2 (en) 2018-02-02 2023-09-26 Cercacor Laboratories, Inc. Limb-worn patient monitoring device
US10952616B2 (en) 2018-03-30 2021-03-23 Canon U.S.A., Inc. Fluorescence imaging apparatus
WO2019204368A1 (en) 2018-04-19 2019-10-24 Masimo Corporation Mobile patient alarm display
WO2019209915A1 (en) 2018-04-24 2019-10-31 Cercacor Laboratories, Inc. Easy insert finger sensor for transmission based spectroscopy sensor
CN112512406A (en) 2018-06-06 2021-03-16 梅西莫股份有限公司 Opioid overdose monitoring
US10779098B2 (en) 2018-07-10 2020-09-15 Masimo Corporation Patient monitor alarm speaker analyzer
US11872156B2 (en) 2018-08-22 2024-01-16 Masimo Corporation Core body temperature measurement
US10743749B2 (en) 2018-09-14 2020-08-18 Canon U.S.A., Inc. System and method for detecting optical probe connection
USD999246S1 (en) 2018-10-11 2023-09-19 Masimo Corporation Display screen or portion thereof with a graphical user interface
CN112997366A (en) 2018-10-11 2021-06-18 迈心诺公司 Patient connector assembly with vertical detent
USD998631S1 (en) 2018-10-11 2023-09-12 Masimo Corporation Display screen or portion thereof with a graphical user interface
USD917564S1 (en) 2018-10-11 2021-04-27 Masimo Corporation Display screen or portion thereof with graphical user interface
USD916135S1 (en) 2018-10-11 2021-04-13 Masimo Corporation Display screen or portion thereof with a graphical user interface
USD917550S1 (en) 2018-10-11 2021-04-27 Masimo Corporation Display screen or portion thereof with a graphical user interface
US11389093B2 (en) 2018-10-11 2022-07-19 Masimo Corporation Low noise oximetry cable
US11406286B2 (en) 2018-10-11 2022-08-09 Masimo Corporation Patient monitoring device with improved user interface
USD998630S1 (en) 2018-10-11 2023-09-12 Masimo Corporation Display screen or portion thereof with a graphical user interface
AU2019357721A1 (en) 2018-10-12 2021-05-27 Masimo Corporation System for transmission of sensor data using dual communication protocol
US11464410B2 (en) 2018-10-12 2022-10-11 Masimo Corporation Medical systems and methods
USD897098S1 (en) 2018-10-12 2020-09-29 Masimo Corporation Card holder set
US11684296B2 (en) 2018-12-21 2023-06-27 Cercacor Laboratories, Inc. Noninvasive physiological sensor
US11633129B2 (en) 2019-04-05 2023-04-25 Cambridge Medical Technologies LLC Non-invasive transdermal sampling and analysis device incorporating redox cofactors
AU2020259445A1 (en) 2019-04-17 2021-12-02 Masimo Corporation Patient monitoring systems, devices, and methods
US11375931B2 (en) 2019-08-08 2022-07-05 Cambridge Medical Technologies LLC Non-invasive transdermal sampling and analysis device incorporating an electrochemical bioassay
USD921202S1 (en) 2019-08-16 2021-06-01 Masimo Corporation Holder for a blood pressure device
USD919094S1 (en) 2019-08-16 2021-05-11 Masimo Corporation Blood pressure device
USD985498S1 (en) 2019-08-16 2023-05-09 Masimo Corporation Connector
USD917704S1 (en) 2019-08-16 2021-04-27 Masimo Corporation Patient monitor
USD919100S1 (en) 2019-08-16 2021-05-11 Masimo Corporation Holder for a patient monitor
US11832940B2 (en) 2019-08-27 2023-12-05 Cercacor Laboratories, Inc. Non-invasive medical monitoring device for blood analyte measurements
USD927699S1 (en) 2019-10-18 2021-08-10 Masimo Corporation Electrode pad
WO2021077019A1 (en) 2019-10-18 2021-04-22 Masimo Corporation Display layout and interactive objects for patient monitoring
WO2021163447A1 (en) 2020-02-13 2021-08-19 Masimo Corporation System and method for monitoring clinical activities
US11879960B2 (en) 2020-02-13 2024-01-23 Masimo Corporation System and method for monitoring clinical activities
US20210290177A1 (en) 2020-03-20 2021-09-23 Masimo Corporation Wearable device for monitoring health status
USD933232S1 (en) 2020-05-11 2021-10-12 Masimo Corporation Blood pressure monitor
USD979516S1 (en) 2020-05-11 2023-02-28 Masimo Corporation Connector
USD980091S1 (en) 2020-07-27 2023-03-07 Masimo Corporation Wearable temperature measurement device
USD974193S1 (en) 2020-07-27 2023-01-03 Masimo Corporation Wearable temperature measurement device
US10952655B1 (en) * 2020-09-21 2021-03-23 The Florida International University Board Of Trustees Retinal blood vessel oximetry using retinal auofluorescence
USD946598S1 (en) 2020-09-30 2022-03-22 Masimo Corporation Display screen or portion thereof with graphical user interface
USD946596S1 (en) 2020-09-30 2022-03-22 Masimo Corporation Display screen or portion thereof with graphical user interface
USD946597S1 (en) 2020-09-30 2022-03-22 Masimo Corporation Display screen or portion thereof with graphical user interface
USD997365S1 (en) 2021-06-24 2023-08-29 Masimo Corporation Physiological nose sensor
USD1000975S1 (en) 2021-09-22 2023-10-10 Masimo Corporation Wearable temperature measurement device

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989012223A1 (en) * 1988-06-08 1989-12-14 Barbour Randall L A method of imaging a random medium
US5122974A (en) * 1989-02-06 1992-06-16 Nim, Inc. Phase modulated spectrophotometry
EP0703445A2 (en) * 1994-09-22 1996-03-27 Hamamatsu Photonics K.K. Method and apparatus for measuring concentration of absorptive constituent in scattering medium
WO1997008538A1 (en) * 1995-08-24 1997-03-06 Purdue Research Foundation Fluorescence lifetime-based imaging and spectroscopy in tissues and other random media

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE23752T1 (en) * 1980-08-21 1986-12-15 Oriel Scient Ltd OPTICAL ANALYZER.
US4569354A (en) * 1982-03-22 1986-02-11 Boston University Method and apparatus for measuring natural retinal fluorescence
JPS60209146A (en) * 1984-03-31 1985-10-21 Olympus Optical Co Ltd Fluorescence spectrochemical analysis device
SE455646B (en) * 1984-10-22 1988-07-25 Radians Innova Ab FLUORESCENT DEVICE
DE3535652A1 (en) * 1984-11-01 1986-04-30 Jenoptik Jena Gmbh, Ddr 6900 Jena ARRANGEMENT FOR OPTICAL RADIATION IN PHOTOMETRIC ANALYZER MEASURING DEVICES
US4641650A (en) * 1985-03-11 1987-02-10 Mcm Laboratories, Inc. Probe-and-fire lasers
CN85100424B (en) * 1985-04-01 1986-10-29 上海医疗器械研究所 Natural fluorscence diagnosis instrument used for diagnosising malignant tumour
US4945245A (en) * 1986-01-14 1990-07-31 Levin Herman W Evanescent wave background fluorescence/absorbance detection
US4996421A (en) * 1988-10-31 1991-02-26 Amoco Corporation Method an system of geophysical exploration
US5419323A (en) * 1988-12-21 1995-05-30 Massachusetts Institute Of Technology Method for laser induced fluorescence of tissue
US5187672A (en) * 1989-02-06 1993-02-16 Nim Incorporated Phase modulation spectroscopic system
CA2042075C (en) * 1991-05-08 2001-01-23 Branko Palcic Endoscopic imaging system
US5635402A (en) * 1992-03-05 1997-06-03 Alfano; Robert R. Technique for determining whether a cell is malignant as opposed to non-malignant using extrinsic fluorescence spectroscopy
US5452723A (en) * 1992-07-24 1995-09-26 Massachusetts Institute Of Technology Calibrated spectrographic imaging
US5341805A (en) * 1993-04-06 1994-08-30 Cedars-Sinai Medical Center Glucose fluorescence monitor and method
US5349954A (en) * 1993-07-23 1994-09-27 General Electric Company Tumor tissue characterization apparatus and method
US5456252A (en) * 1993-09-30 1995-10-10 Cedars-Sinai Medical Center Induced fluorescence spectroscopy blood perfusion and pH monitor and method
US5515864A (en) * 1994-04-21 1996-05-14 Zuckerman; Ralph Method and apparatus for the in vivo measurement of oxygen concentration levels by the indirect determination of fluoescence lifetime
US5760406A (en) * 1996-06-03 1998-06-02 Powers; Linda Method and apparatus for sensing the presence of microbes
US6124597A (en) 1997-07-07 2000-09-26 Cedars-Sinai Medical Center Method and devices for laser induced fluorescence attenuation spectroscopy
US6219575B1 (en) * 1998-10-23 2001-04-17 Babak Nemati Method and apparatus to enhance optical transparency of biological tissues

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989012223A1 (en) * 1988-06-08 1989-12-14 Barbour Randall L A method of imaging a random medium
US5122974A (en) * 1989-02-06 1992-06-16 Nim, Inc. Phase modulated spectrophotometry
EP0703445A2 (en) * 1994-09-22 1996-03-27 Hamamatsu Photonics K.K. Method and apparatus for measuring concentration of absorptive constituent in scattering medium
WO1997008538A1 (en) * 1995-08-24 1997-03-06 Purdue Research Foundation Fluorescence lifetime-based imaging and spectroscopy in tissues and other random media

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE39672E1 (en) 1997-07-07 2007-06-05 Cedars-Sinai Medical Center Method and devices for laser induced fluorescence attenuation spectroscopy
US6587702B1 (en) 1999-01-22 2003-07-01 Instrumentation Metrics, Inc Classification and characterization of tissue through features related to adipose tissue
WO2001052725A1 (en) * 2000-01-21 2001-07-26 Instrumentation Metrics, Inc. Classification and characterization of tissue through features related to adipose tissue
WO2001060246A2 (en) * 2000-02-18 2001-08-23 Argose, Inc. Multivariate analysis of green to ultraviolet spectra of cell and tissue samples
WO2001060246A3 (en) * 2000-02-18 2002-02-28 Argose Inc Multivariate analysis of green to ultraviolet spectra of cell and tissue samples
JP4954418B2 (en) * 2000-03-31 2012-06-13 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ Method and apparatus for locating anomalous regions in turbid media
US6377841B1 (en) 2000-03-31 2002-04-23 Vanderbilt University Tumor demarcation using optical spectroscopy
JP2003528678A (en) * 2000-03-31 2003-09-30 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ Method and apparatus for localizing anomalous regions in a turbid medium
WO2002024048A2 (en) 2000-09-25 2002-03-28 Vital Medical Ltd. Apparatus and method for monitoring tissue vitality parameters
WO2002024048A3 (en) * 2000-09-25 2002-07-18 Vital Medical Ltd Apparatus and method for monitoring tissue vitality parameters
US7130672B2 (en) 2000-09-25 2006-10-31 Critisense Ltd. Apparatus and method for monitoring tissue vitality parameters
US7313424B2 (en) 2002-03-20 2007-12-25 Critisense Ltd. Diagnosis of body metabolic emergency state
WO2004039254A1 (en) * 2002-10-31 2004-05-13 Shanghai Shengbiao Science And Technology Co., Ltd. A laser-induced fluorescence method for precancerous lesion diagnosis and an endoscope precancerous lesion diagnosis apparatus thereof
US7558609B2 (en) 2004-04-06 2009-07-07 National University Corporation Okayama University Cerebral-ischemia supervisory monitor
JP2016540558A (en) * 2013-11-14 2016-12-28 ザ・ジョージ・ワシントン・ユニバーシティThe George Washingtonuniversity System and method for determining the depth of damage using fluorescence imaging
WO2016166067A1 (en) * 2015-04-17 2016-10-20 Koninklijke Philips N.V. Detection of anisotropic biological tissue
CN107529992A (en) * 2015-04-17 2018-01-02 皇家飞利浦有限公司 The detection of anisotropic biological tissue
US11202606B2 (en) 2015-04-17 2021-12-21 Koninklijke Philips N.V. Detection of anisotropic biological tissue
CN109270044A (en) * 2018-11-28 2019-01-25 安徽理工大学 A kind of laser induced fluorescence vegetable oil doping strong tea water identification method

Also Published As

Publication number Publication date
EP1562038A3 (en) 2005-11-23
US6124597A (en) 2000-09-26
AU7830698A (en) 1999-02-08
DE69829664D1 (en) 2005-05-12
EP0995095B1 (en) 2005-04-06
USRE39672E1 (en) 2007-06-05
EP1562038A2 (en) 2005-08-10
WO1999002956A3 (en) 1999-04-29
US6697657B1 (en) 2004-02-24
AU752061B2 (en) 2002-09-05
JP2001509589A (en) 2001-07-24
EP0995095A2 (en) 2000-04-26

Similar Documents

Publication Publication Date Title
US6124597A (en) Method and devices for laser induced fluorescence attenuation spectroscopy
Ge et al. Identification of colonic dysplasia and neoplasia by diffuse reflectance spectroscopy and pattern recognition techniques
US8532726B2 (en) Invasive chemometry
US7330746B2 (en) Non-invasive biochemical analysis
EP2198268B1 (en) Optical apparatus for determining a blood characteristic
US5421337A (en) Spectral diagnosis of diseased tissue
JP5982364B2 (en) Apparatus and method for identifying and monitoring components or characteristics of a measurement medium, in particular physiological blood values
JP3875798B2 (en) Method of operating a bloodless measuring device for blood component concentration and bloodless measuring device
US6002953A (en) Non-invasive IR transmission measurement of analyte in the tympanic membrane
US11147482B2 (en) Method and system for non-invasive blood glucose measurement using signal change of the non-glucose components induced by the presence of glucose
US5876121A (en) Substrate temperature measurement by infrared spectroscopy
US7961305B2 (en) Optical device components
US6088087A (en) Transcutaneous measurement of substance in body tissues or fluid
US20080200780A1 (en) Optical measurement of cellular energetics
JPH11510254A (en) Optical microprobe and method for spectral analysis of materials
US20230148312A1 (en) Device for non-invasive blood glucose concentration measurement
CN112244822A (en) Tissue oxygen metabolism rate detection device and method based on near-infrared broadband spectrum
KR100883153B1 (en) Instrument for noninvasively measuring blood sugar level
KR100300960B1 (en) Method and device for noninvasive determination of the concentrations of blood components

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1998926475

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 78306/98

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 1998926475

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 78306/98

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 1998926475

Country of ref document: EP